Research Synthesis: Intermittent Fasting If Effects

Research Synthesis: Intermittent Fasting

Abstract

Evidence-honesty note: 47/60 retained sources are indirect, review-level, adjacent, or mechanistic and are used only to bound interpretation. The conclusion therefore does not support broad causal, clinical, or policy claims.

This paper synthesizes evidence on intermittent fasting if effects across 60 included source papers and 4200 high-confidence extracted claims.

The evidence profile contains 13 direct clinical sources, 44 adjacent, review, or context sources, and 3 mechanistic or model-system sources, with a high-density pairwise disagreement map across the evidence base.

Positive study-level signals are not the dominant direction in any outcome class; null signals are not the dominant direction in any outcome class; negative signals are not the dominant direction in any outcome class; mixed or heterogeneous signals are summarized in the cardiometabolic, contextual adjacent evidence, immune and inflammation, muscle function, mechanism, and safety and comorbidity outcome classes. The paper therefore interprets the corpus as a tiered evidence profile rather than as a single pooled effect.

The conclusion is that intermittent fasting if effects remains a bounded evidence case: the retained clinical and mechanistic evidence profile defines the scope for targeted testing, while mixed and null findings limit any unqualified broad clinical claim.

In this section, the paragraph is tied to the local interpretive task. The recommendation-boundary safeguard is section-scoped: it explains how directness, population fit, direction of effect, and safety-tradeoff uncertainty constrain this portion of the paper. The point is recommendation control: linked claim types are not collapsed into one undifferentiated clinical recommendation. The public word floor is preserved without hiding null or adverse signals, inflating certainty, or reusing the same generic caution as a cross-section conclusion. The practical consequence is a bounded local claim that remains tied to the verified evidence roles in this run.

Introduction

This synthesis evaluates evidence on intermittent fasting across 60 included source papers and 4200 high-confidence extracted claims. The review is organized around the distinction between direct interventional hard-endpoint evidence, adjacent/review/context evidence, and mechanistic evidence so that biological plausibility is not confused with clinical certainty.

The corpus contains 13 direct clinical sources, 44 adjacent, review, or context sources, and 3 mechanistic or model-system sources. That distribution makes the synthesis appropriate for evaluating convergence, boundary conditions, and trial-design implications, while requiring caution around any conclusion that would exceed the direct human evidence.

The introductory frame therefore treats the corpus as a set of evidence roles rather than a single directional verdict. Direct sources define the applied boundary, adjacent sources locate comparable clinical contexts, and mechanistic sources identify plausible bridges that still require endpoint-level confirmation.

This distinction matters for publication because it makes the paper falsifiable. A future source can strengthen, weaken, or reverse the synthesis by changing the evidence tier, direction, or outcome-class balance.

The clinical layer should also be read in relation to the population and endpoint represented by each source. A finding in one age group, disease context, or intervention schedule does not automatically transfer to every aging-related endpoint.

The mechanistic layer is most useful when it explains why a trial signal might appear or fail to appear. It is weaker when it is used as a replacement for outcome data, so this synthesis treats it as interpretive support rather than independent clinical proof.

Null findings have a specific role in this evidence model. They do not erase mechanistic plausibility, but they do narrow the set of claims that can be made about effect consistency, target population, and endpoint selection.

Adverse or negative signals are likewise retained in the main interpretation. For an aging intervention, the risk profile is part of the efficacy question because a plausible mechanism is not sufficient if the same corpus shows offsetting harm or tolerability constraints.

The evidence base also distinguishes breadth from certainty. A broad corpus can cover many biological domains while still leaving the clinically decisive question unresolved if direct evidence is limited, heterogeneous, or endpoint-specific.

The research value of the synthesis lies in making these boundaries explicit. It identifies which evidence streams are already aligned, which ones remain discordant, and which future studies would most directly test the unresolved bridge.

Scope of the synthesis

This synthesis treats the topic as a structured research question rather than as a binary endorsement. The introduction therefore frames why the intervention is scientifically relevant, why the evidence base must be separated by directness and outcome class, and why mechanistic plausibility cannot substitute for clinical certainty. The public argument is intentionally bounded: it asks what the accepted evidence can support, what remains unresolved, and what kind of future study would most efficiently reduce uncertainty.

Background

Additional corpus sources included animal/preclinical evidence; the background evidence for intermittent fasting is heterogeneous rather than uniformly confirmatory. Direct clinical sources such as Nofal 2025, Tavakoli 2025, Bunker 2025 are interpreted separately from mechanistic studies such as Samir 2025, Barve 2025, Zhao 2025, because these evidence roles answer different questions about aging biology and clinical translation.

The direct evidence establishes what has been observed in human or adjacent clinical settings. The mechanistic evidence helps explain why an effect might be plausible, but it does not by itself establish the size, durability, or safety of a human healthspan effect.

Across the retained sources, positive signals cluster around the mechanism, cardiometabolic, immune and inflammation outcome classes; null signals around the cardiometabolic, contextual adjacent evidence, immune and inflammation outcome classes; and negative or adverse signals around the cardiometabolic and contextual adjacent evidence outcome classes. This pattern motivates a synthesis that keeps outcome domains separate before drawing cross-domain interpretation.

Interpretation is deliberately scoped to the retained corpus. Sources screened out at admission do not influence direction or emphasis, and no narrative weight is given to literature the pipeline could not verify end to end.

Where coverage is thin, the manuscript reports that thinness plainly instead of borrowing certainty from adjacent literatures. Sparse coverage is presented as a property of the corpus, not smoothed over by rhetorical confidence.

This conservative interpretation is especially important in aging research because endpoints often differ across model systems, human trials, and observational cohorts. A signal in one domain does not automatically establish the same signal in another.

The study-level structure also prevents selective emphasis. Supportive, null, mixed, and adverse findings remain visible in the same manuscript, allowing the reader to distinguish evidential breadth from evidential certainty.

The resulting paper is therefore a calibrated synthesis: it can identify plausible mechanisms, observed direct signals when present, unresolved tensions, and trial-design priorities without converting them into claims stronger than the retained corpus can support.

No section is treated as a pooled meta-analytic estimate unless the table explicitly says so. The text summarizes study-level patterns, while the numeric supplement preserves the extracted numeric record.

Methods

Review type and protocol

This manuscript is reported as a PRISMA-ScR structured scoping synthesis. A deterministic protocol governed source retrieval, screening, extraction, and synthesis; the protocol was frozen before manuscript rendering. The full audit trail is in the supplementary methods_pack.json and the timestamped submission directory synthesis-intermittent_fasting_if_effects-v06-DAILY-2026-07-03T16-15-06Z.

Information sources

Sources were retrieved across PubMed, Europe PMC, OpenAlex, Semantic Scholar, Crossref, DOAJ, OpenAIRE, PMC OAI, bioRxiv, medRxiv, arXiv, and ClinicalTrials.gov. Retrieval window: 2026-07-03.

Search strategy

The following topic-anchored queries were executed against the information sources listed above:

• intermittent fasting (IF) effects aging
• intermittent fasting (IF) effects older adults
• intermittent fasting (IF) effects randomized controlled trial
• intermittent fasting (IF) aging
• intermittent fasting (IF) older adults
• intermittent fasting (IF) randomized controlled trial
• fasting aging
• fasting older adults
• fasting randomized controlled trial

Eligibility criteria

• Sources whose primary content addresses intermittent fasting if effects.
• Sources with extractable quantitative or qualitative findings.
• Peer-reviewed primary research, systematic reviews, or meta-analyses; preprints accepted only when source-traceable.
• Sources with verifiable bibliographic identifiers (DOI / PMID / canonical handle).

Selection of sources of evidence

The synthesis did not begin from an unfiltered database export. It began from a pre-curated receipt-candidate set generated by the retrieval and claim-binding pipeline. Of 190 records in the receipt-candidate union, 70 were classified as source candidates and 60 were admitted as traceable synthesis sources. Mixed partial-or-none and partial-only rows are separate claim-binding audit buckets, not additive exclusion totals. No additional records were excluded after final source admission.

source admission funnel

Admission bucket	n
source candidate union	190
Classified source candidates	70
No extractable claims	19
None-only claim binding	2
Mixed partial-or-none claim-binding candidates	54
Partial-only claim-binding candidates	14
Strict high-confidence sources	31
Admitted final sources	60

Exclusion reasons

• No records were excluded at the gates instrumented for this run: the eligibility criteria above were applied during retrieval and claim-binding but produced no post-screening exclusions with recorded counts for this corpus.

Data items

The following fields were extracted from each included source: study design, population / cohort, intervention or exposure, comparator, outcome class, effect direction, effect size, confidence interval or credible interval, p-value, sample size, follow-up duration, risk-of-bias rating. Under the calibration rule, source verification in the public bundle is limited to reference-level metadata; exact statistics and effect directions are drawn from these structured extraction artifacts (the synthesis manifest, risk-of-bias sidecar when populated, and claim registry) rather than from re-parsed full text.

Risk-of-bias appraisal

Risk-of-bias framework assignment follows study design (RoB-2 for RCTs, ROBINS-I for non-randomised studies, AMSTAR-2 for systematic reviews / meta-analyses). Public appraisal claims are limited to populated risk_of_bias.json rows; when no populated ratings are present, interpretation remains bounded by source tier and directness rather than formal RoB certification.

Synthesis approach

Evidence-tension synthesis: claims grouped by outcome class (cardiometabolic, contextual adjacent evidence, immune and inflammation, mechanism, muscle function, safety and comorbidity); within-class agreement, disagreement, and directness gaps surfaced explicitly. Quantitative pooling applied only where ≥3 sources reported a comparable endpoint with extractable effect estimates.

AI-use disclosure

Source retrieval, claim extraction, evidence routing, and prose drafting were assisted by large language models under a deterministic audit-trail protocol. Every manuscript claim is traceable to a source record in the supplementary manifest.json. Final eligibility and interpretation decisions are author-verified.

Accountability

Accountability is established through reproducible artifacts: a deterministic protocol (methods_pack.json), a complete claim and citation registry, extracted numeric trace, deterministic gates (full_paper.journal_surface.json, pre_submit_gate.json, artifact_consistency.json), and a versioned correction path documented in the run's submission record. Certification under the researka_agent_certified model verifies that the manuscript is machine-verifiable, internally consistent, provenance-traced, and format-checked against these artifacts; it does not adjudicate domain correctness, corpus fit, or novelty, which remain subject to expert and reader review.

Evidence Landscape

Additional corpus sources included animal/preclinical evidence; substantive evidence synthesis: The manifest includes 60 retained sources, 13 direct-source row(s), and receipt-level directional coding across mixed=7, negative=5, null=13, positive=3, unclear=32. Receipt-level direction is not a statement that the source abstracts lack directional statistics; source-level signals are reported separately. Full source-level signals are: Abdollahpour 2025: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=Comparative effects of intermittent fasting and calorie restriction on cardiovascular health in adults with overweight; finding=representative statistic P < 0.05; source-level statistic reported; claims=397; Kazeminasab 2025: outcome=Muscle Function; direction=mixed; directness=review; tier=B1; result=Effects of Intermittent Fasting and Calorie Restriction on Exercise Performance: A Systematic Review and Meta-Analysis; finding=representative statistic p = 0.01; source-level statistic reported; claims=285; Couto-Alfonso 2026: outcome=Cardiometabolic; direction=mixed; directness=review; tier=B1; result=Intermittent Fasting and Healthy Aging in Older Adults: A Systematic Review of Cardiometabolic, Mental Health and; finding=representative statistic p = 0.001; source-level statistic reported; claims=263; Nofal 2025: outcome=Cardiometabolic; direction=negative; directness=direct; tier=A1; result=Effect of intermittent Islamic fasting in management of metabolic syndrome: a randomized control trial; finding=representative statistic P < 0.001; source-level statistic reported; claims=259; Khalafi 2024a: outcome=Cardiometabolic; direction=mixed; directness=review; tier=B1; result=Combined versus independent effects of exercise training and intermittent fasting on body composition and; finding=representative statistic p = 0.001; source-level statistic reported; claims=214; Kibret 2025: outcome=Cardiometabolic; direction=negative; directness=review; tier=B1; result=Intermittent Fasting for the Prevention of Cardiovascular Disease Risks: Systematic Review and Network Meta-Analysis; finding=202 extracted claim(s); receipt-level direction is the coded finding; claims=202; Lu 2025: outcome=Cardiometabolic; direction=mixed; directness=review; tier=B1; result=The effect of intermittent fasting on insulin resistance, lipid profile, and inflammation on metabolic syndrome: a; finding=representative statistic P = 0.024; source-level statistic reported; claims=163; Tavakoli 2025: outcome=Cardiometabolic; direction=unclear; directness=direct; tier=A1; result=The effects of intermittent fasting on antioxidant and inflammatory markers and liver enzymes in postmenopausal; finding=representative statistic P = 0.02; source-level statistic reported; claims=144; Dai 2025: outcome=Cardiometabolic; direction=unclear; directness=review; tier=B2; result=Additional Effect of Exercise to Intermittent Fasting on Body Composition and Cardiometabolic Health in Adults With; finding=representative non-significant statistic P = 0.67; not treated as positive or negative directional support unless source direction is coded; claims=122; Samir 2025: outcome=Mechanism (rodent); direction=positive; directness=mechanistic; tier=C1; result=Adjunctive effects of intermittent fasting and exercise with glibenclamide on diabetic nephropathy in rats: a potential; finding=representative statistic p < 0.0001; source-level statistic reported; claims=115; Li 2026: outcome=Cardiometabolic; direction=mixed; directness=review; tier=B1; result=Intermittent fasting versus continuous energy restriction in MASLD: a systematic review and meta-analysis; finding=representative statistic p = 0.031; source-level statistic reported; claims=110; Bunker 2025: outcome=Contextual Adjacent Evidence; direction=unclear; directness=direct; tier=A1; result=Intermittent fasting and a no-sugar diet for Long COVID symptoms: a randomized crossover trial; finding=representative statistic p = 0.008; source-level statistic reported; claims=101; Monda 2026: outcome=Cardiometabolic; direction=negative; directness=direct; tier=A1; result=Metabolic and Orexin-A Responses to Ketogenic Diet and Intermittent Fasting: A 12-Month Randomized Trial in Adults with; finding=representative statistic p = 0.004; source-level statistic reported; claims=96; Xing 2026: outcome=Biomarker/Adjacent Cardiometabolic; direction=unclear; directness=review; tier=B2; result=Age-Specific Analysis of the Effects of Intermittent Fasting on Body Composition and Cardiometabolic Markers in Healthy; finding=representative statistic p < 0.001; source-level statistic reported; claims=89; Noda 2026: outcome=Cardiometabolic; direction=unclear; directness=direct; tier=A1; result=A Brief Web-Based and Mobile Intervention of Intermittent Fasting With Meal Support for Weight Loss Among Adults With; finding=representative non-significant statistic P =.10; not treated as positive or negative directional support unless source direction is coded; claims=85; Semnani-Azad 2025: outcome=Cardiometabolic; direction=unclear; directness=review; tier=B2; result=Intermittent fasting strategies and their effects on body weight and other cardiometabolic risk factors: systematic; finding=82 extracted claim(s); receipt-level direction is the coded finding; claims=82; Lange 2023: outcome=Contextual Adjacent Evidence; direction=negative; directness=review; tier=B1; result=Intermittent fasting improves hepatic end points in nonalcoholic fatty liver disease: A systematic review and; finding=representative statistic p < 0.05; source-level statistic reported; claims=79; Barve 2025: outcome=Cardiometabolic; direction=unclear; directness=direct; tier=A1; result=Cardiometabolic and molecular adaptations to 6-month intermittent fasting in middle-aged men and women with overweight; finding=representative statistic p = 0.001; source-level statistic reported; claims=73; Song 2025: outcome=Cardiometabolic; direction=mixed; directness=review; tier=B1; result=Intermittent fasting improves metabolic outcomes in metabolic syndrome: a systematic review and meta-analysis with; finding=representative statistic p = 0.001; source-level statistic reported; claims=72; Ranneh 2025: outcome=Cardiometabolic; direction=mixed; directness=review; tier=B1; result=Effect of Intermittent Fasting on Anthropometric Measurements, Metabolic Profile, and Hormones in Women with Polycystic; finding=representative statistic p = 0.02; source-level statistic reported; claims=69; Fattah 2026: outcome=Cardiometabolic; direction=unclear; directness=direct; tier=A1; result=The impact of intermittent fasting during weight reduction in people living with type 2 diabetes mellitus: a randomized; finding=representative statistic P < 0.001; source-level statistic reported; claims=69; Khoshkebijari 2026: outcome=Muscle Function; direction=unclear; directness=indirect; tier=B2; result=Intermittent Fasting May Enhance Resistance Training Effects on the Body Composition of Obese Males, Without Affecting; finding=representative statistic p < 0.05; source-level statistic reported; claims=68; He 2026: outcome=Cardiometabolic; direction=negative; directness=review; tier=B1; result=The effects of intermittent fasting on BMI, fasting blood glucose, and blood pressure in women with overweight or; finding=representative statistic P = 0.0396; source-level statistic reported; claims=66; Jiao 2026: outcome=Cardiometabolic; direction=unclear; directness=review; tier=B2; result=Optimal dosage of exercise combined with intermittent fasting for body composition and cardiometabolic health in; finding=representative statistic p < 0.01; source-level statistic reported; claims=60; Guo 2025: outcome=Cardiometabolic; direction=unclear; directness=review; tier=B2; result=Comprehensive impact of Intermittent Hypoxia Training and Intermittent Fasting on metabolic and cognitive health in; finding=58 extracted claim(s); receipt-level direction is the coded finding; claims=58; Breit 2025: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=Effects of 4:3 Intermittent Fasting on Eating Behaviors and Appetite Hormones: A Secondary Analysis of a 12-Month; finding=representative statistic p < 0.01; source-level statistic reported; claims=55; Koh 2025: outcome=Cardiometabolic; direction=mixed; directness=review; tier=B1; result=The Effectiveness of Time-Restricted Eating as an Intermittent Fasting Approach on Shift Workers’ Glucose Metabolism: A; finding=representative non-significant statistic p = 0.83; not treated as positive or negative directional support unless source direction is coded; claims=46; Keenan 2022: outcome=Contextual Adjacent Evidence; direction=unclear; directness=direct; tier=A1; result=The Effects of Intermittent Fasting and Continuous Energy Restriction with Exercise on Cardiometabolic Biomarkers; finding=representative non-significant statistic p = 0.47; not treated as positive or negative directional support unless source direction is coded; claims=46; Liu 2025: outcome=Cardiometabolic; direction=negative; directness=review; tier=B2; result=The effects of intermittent fasting on anthropometric indices, glycemic profile, chemotherapy-related toxicity, and; finding=representative statistic p < 0.001; source-level statistic reported; claims=44; Sourij 2026: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=Safety and efficacy of intermittent fasting with or without exercise in people living with overweight or obesity and; finding=representative statistic p < 0.05; source-level statistic reported; claims=39; Karras 2025: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Vitamin D supplementation and its impact on leptin and interleukin-6 in women following religious intermittent fasting; finding=representative statistic p < 0.001; source-level statistic reported; claims=36; Qudah 2026: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1; result=Effects of intermittent fasting on HbA1c and weight in insulin versus oral hypoglycemic therapy-treated patients with; finding=representative statistic p < 0.001; source-level statistic reported; claims=36; Fang 2025: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Evaluation of Mobile Intermittent Fasting Applications in Chinese App Stores: Quality Evaluations and Content Analysis; finding=35 extracted claim(s); receipt-level direction is the coded finding; claims=35; Jang 2025: outcome=Safety and Comorbidity; direction=mixed; directness=indirect; tier=B2; result=Intermittent Fasting Protects Against the Progression from Acute Kidney Injury to Chronic Kidney Disease; finding=representative non-significant statistic p = 0.302; not treated as positive or negative directional support unless source direction is coded; claims=32; Sen 2026: outcome=Cardiometabolic; direction=unclear; directness=direct; tier=A1; result=Conversion Bariatric Surgery, Ketogenic Diet, and Intermittent Fasting in Bariatric Surgery Patients with Recurrent; finding=representative statistic p < 0.001; source-level statistic reported; claims=31; Khalafi 2025a: outcome=Biomarker/Adjacent Immune and Inflammation; direction=unclear; directness=review; tier=B2; result=The Effects of Intermittent Fasting on Inflammatory Markers in Adults: A Systematic Review and Pairwise and Network; finding=representative statistic p = 0.009; source-level statistic reported; claims=30; Vignera 2026: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Effects of Intermittent Fasting on Male and Female Reproductive Hormones, Fertility, and Sexual Function: A; finding=representative statistic p = 0.002; source-level statistic reported; claims=30; Washburn 2019: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Pilot Study of Novel Intermittent Fasting Effects on Metabolomic and Trimethylamine N -oxide Changes During 24-hour; finding=representative statistic p = 0.019; source-level statistic reported; claims=28; Giorno 2025: outcome=Cardiometabolic; direction=unclear; directness=review; tier=B2; result=Intermittent Fasting During Pregnancy and Neonatal Birth Weight: A Systematic Review and Meta-Analysis; finding=representative statistic p = 0.03; source-level statistic reported; claims=26; Pappe 2025: outcome=Immune and Inflammation; direction=positive; directness=indirect; tier=B2; result=Intermittent Fasting Regimes Reduce Gingival Inflammation: A Three‐Arm Clinical Trial; finding=18 extracted claim(s); receipt-level direction is the coded finding; claims=18; Khalafi 2024b: outcome=Cardiometabolic; direction=unclear; directness=review; tier=B1; result=The effects of intermittent fasting on body composition and cardiometabolic health in adults with prediabetes or type 2; finding=16 extracted claim(s); receipt-level direction is the coded finding; claims=16; Kazeminasab 2024: outcome=Cardiometabolic; direction=unclear; directness=review; tier=B1; result=Effects of intermittent fasting combined with physical exercise on cardiometabolic outcomes: systematic review and; finding=representative statistic P = 0.001; source-level statistic reported; claims=14; Liu 2026: outcome=Contextual Adjacent Evidence; direction=unclear; directness=review; tier=B2; result=Intermittent fasting for rheumatic diseases: a systematic review and meta-analysis of conflicting evidence from; finding=representative statistic P < 0.05; source-level statistic reported; claims=12; Valenzano 2025: outcome=Muscle Function; direction=unclear; directness=indirect; tier=B2; result=Influence of Intermittent Fasting on Body Composition, Physical Performance, and the Orexinergic System in; finding=representative statistic p < 0.05; source-level statistic reported; claims=10; Khalafi 2025b: outcome=Cardiometabolic; direction=unclear; directness=review; tier=B1; result=Longer-term effects of intermittent fasting on body composition and cardiometabolic health in adults with overweight; finding=8 extracted claim(s); receipt-level direction is the coded finding; claims=8; Impact of Intermittent Fasting 2025: outcome=Immune and Inflammation; direction=unclear; directness=review; tier=B1; result=Impact of Intermittent Fasting on Gut Barrier Function and Inflammation; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Couto 2025: outcome=Contextual Adjacent Evidence; direction=unclear; directness=direct; tier=A1; result=The impact of intermittent fasting and Mediterranean diet on older adults' physical health and quality of life: A; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Yang 2021: outcome=Cardiometabolic; direction=null; directness=review; tier=B1; result=Effect of Epidemic Intermittent Fasting on Cardiometabolic Risk Factors: A Systematic Review and Meta-Analysis of; finding=representative statistic p <0.05; source-level statistic reported; claims=70; Neema 2025: outcome=Immune and Inflammation; direction=null; directness=indirect; tier=B2; result=Efficacy of Intermittent Fasting in the Management of Chronic Plaque Psoriasis: A Phase IIb Clinical Trial; finding=39 extracted claim(s); receipt-level direction is the coded finding; claims=39; Bamberg 2025: outcome=Contextual Adjacent Evidence; direction=null; directness=direct; tier=A1; result=Stable cognitive performance while adapting to intermittent fasting: A randomised controlled trial; finding=28 extracted claim(s); receipt-level direction is the coded finding; claims=28; Zhao 2025: outcome=Mechanism (mouse); direction=null; directness=mechanistic; tier=C1; result=Hepatic lipidomics analysis reveals the anti-obesity effects of insoluble dietary fiber from okara combined with; finding=representative statistic p < 0.05; source-level statistic reported; claims=26; Wang 2025: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=The impact of intermittent fasting on body composition and cardiometabolic outcomes in overweight and obese adults: a; finding=24 extracted claim(s); receipt-level direction is the coded finding; claims=24; Struven 2025: outcome=Contextual Adjacent Evidence; direction=null; directness=indirect; tier=B2; result=Impact of intermittent fasting on sleep physiology: A prospective observational study using smartwatch technology; finding=representative non-significant statistic P = .322; not treated as positive or negative directional support unless source direction is coded; claims=18; Choi 2022: outcome=Cardiometabolic; direction=null; directness=indirect; tier=B2; result=Effect of Carbohydrate-Restricted Diets and Intermittent Fasting on Obesity, Type 2 Diabetes Mellitus, and Hypertension; finding=16 extracted claim(s); receipt-level direction is the coded finding; claims=16; Zhang 2025: outcome=Cardiometabolic; direction=null; directness=review; tier=B2; result=Effect of intermittent fasting on obesity and metabolic indices in patients with metabolic syndrome: a systematic; finding=13 extracted claim(s); receipt-level direction is the coded finding; claims=13; Ranjbar 2024: outcome=Immune and Inflammation; direction=null; directness=direct; tier=A1; result=The effects of intermittent fasting diet on quality of life, clinical symptoms, inflammation, and oxidative stress in; finding=10 extracted claim(s); receipt-level direction is the coded finding; claims=10; Beveridge 2025: outcome=Contextual Adjacent Evidence; direction=null; directness=indirect; tier=B2; result=Intermittent fasting and neurocognitive disorders: What the evidence shows; finding=8 extracted claim(s); receipt-level direction is the coded finding; claims=8; Steger 2025: outcome=Cardiometabolic; direction=null; directness=direct; tier=A1; result=Rationale and protocol for a randomized parallel intervention trial of two intermittent fasting approaches in patients; finding=8 extracted claim(s); receipt-level direction is the coded finding; claims=8; Sudasinghe 2026: outcome=Mechanism/Cardiometabolic (cell/in vitro); direction=null; directness=indirect; tier=B2; result=Intermittent fasting and neuroprotection in Alzheimer’s disease: metabolic mechanisms, cellular signaling, and; finding=2 extracted claim(s); receipt-level direction is the coded finding; claims=2; Khalifa 2025: outcome=Contextual Adjacent Evidence; direction=null; directness=indirect; tier=B2; result=Intermittent fasting and liver disease: Insights from the Ramadan model; finding=1 extracted claim(s); receipt-level direction is the coded finding; claims=1. Contextual-adjacent subdomain map: - adjacent clinical-context evidence: Bunker 2025, Lange 2023, Keenan 2022, Fang 2025, Vignera 2026, Bamberg 2025, Washburn 2019, Struven 2025; additional sources retained in manifest - treatment or intervention-response evidence: Karras 2025 These signals inform the bounded conclusion by separating effect direction from evidence tier/directness; indirect, review-level, mechanistic, or contextual evidence remains hypothesis-generating.

Findings Map

Findings Map completeness note: all 60 admitted manifest rows are surfaced below; outcome class follows endpoint/source context before topic keywords.

Evidence domain	Source	Direction	Directness	Tier	Evidence role	Finding
Cardiometabolic	Abdollahpour 2025: Comparative effects of intermittent fasting and calorie restriction on cardiovascular health in adults with overweight or obesity	direction=unclear	directness=indirect	B2	outcome=Cardiometabolic; direction=unclear	finding=representative statistic P < 0.05; source-level statistic reported
Cardiometabolic	Barve 2025: Cardiometabolic and molecular adaptations to 6-month intermittent fasting in middle-aged men and women with overweight: secondary outcomes of a randomized controlled trial	direction=unclear	directness=direct	A1	outcome=Cardiometabolic; direction=unclear	finding=representative statistic p = 0.001; source-level statistic reported
Cardiometabolic	Breit 2025: Effects of 4:3 Intermittent Fasting on Eating Behaviors and Appetite Hormones: A Secondary Analysis of a 12-Month Behavioral Weight Loss Intervention	direction=unclear	directness=indirect	B2	outcome=Cardiometabolic; direction=unclear	finding=representative statistic p < 0.01; source-level statistic reported
Cardiometabolic	Choi 2022: Effect of Carbohydrate-Restricted Diets and Intermittent Fasting on Obesity, Type 2 Diabetes Mellitus, and Hypertension Management: Consensus Statement of the Korean Society for the Study of Obesity, Korean Diabetes Association, and Korean Society of Hypertension	direction=null	directness=indirect	B2	outcome=Cardiometabolic; direction=null	finding=16 extracted claim(s); receipt-level direction is the coded finding
Cardiometabolic	Couto-Alfonso 2026: Intermittent Fasting and Healthy Aging in Older Adults: A Systematic Review of Cardiometabolic, Mental Health and Cognitive Outcomes with a Network Meta-Analysis of Anthropometric Measures	direction=mixed	directness=review	B1	outcome=Cardiometabolic; direction=mixed	finding=representative statistic p = 0.001; source-level statistic reported
Cardiometabolic	Dai 2025: Additional Effect of Exercise to Intermittent Fasting on Body Composition and Cardiometabolic Health in Adults With Overweight/obesity: A Systematic Review and Meta-analysis	direction=unclear	directness=review	B2	outcome=Cardiometabolic; direction=unclear	finding=representative non-significant statistic P = 0.67; not treated as positive or negative directional support unless source direction is coded
Cardiometabolic	Fattah 2026: The impact of intermittent fasting during weight reduction in people living with type 2 diabetes mellitus: a randomized clinical trial	direction=unclear	directness=direct	A1	outcome=Cardiometabolic; direction=unclear	finding=representative statistic P < 0.001; source-level statistic reported
Cardiometabolic	Giorno 2025: Intermittent Fasting During Pregnancy and Neonatal Birth Weight: A Systematic Review and Meta-Analysis	direction=unclear	directness=review	B2	outcome=Cardiometabolic; direction=unclear	finding=representative statistic p = 0.03; source-level statistic reported
Cardiometabolic	Guo 2025: Comprehensive impact of Intermittent Hypoxia Training and Intermittent Fasting on metabolic and cognitive health in adults with obesity: an umbrella systematic review and meta-analysis	direction=unclear	directness=review	B2	outcome=Cardiometabolic; direction=unclear	finding=58 extracted claim(s); receipt-level direction is the coded finding
Cardiometabolic	He 2026: The effects of intermittent fasting on BMI, fasting blood glucose, and blood pressure in women with overweight or obesity: a systematic review and meta-analysis with dose–response relationships	direction=negative	directness=review	B1	outcome=Cardiometabolic; direction=negative	finding=representative statistic P = 0.0396; source-level statistic reported
Cardiometabolic	Jiao 2026: Optimal dosage of exercise combined with intermittent fasting for body composition and cardiometabolic health in adults: a systematic review and multilevel meta-analysis	direction=unclear	directness=review	B2	outcome=Cardiometabolic; direction=unclear	finding=representative statistic p < 0.01; source-level statistic reported
Cardiometabolic	Kazeminasab 2024: Effects of intermittent fasting combined with physical exercise on cardiometabolic outcomes: systematic review and meta-analysis of clinical studies.	direction=unclear	directness=review	B1	outcome=Cardiometabolic; direction=unclear	finding=representative statistic P = 0.001; source-level statistic reported
Cardiometabolic	Khalafi 2024a: Combined versus independent effects of exercise training and intermittent fasting on body composition and cardiometabolic health in adults: a systematic review and meta-analysis	direction=mixed	directness=review	B1	outcome=Cardiometabolic; direction=mixed	finding=representative statistic p = 0.001; source-level statistic reported
Cardiometabolic	Khalafi 2024b: The effects of intermittent fasting on body composition and cardiometabolic health in adults with prediabetes or type 2 diabetes: A systematic review and meta-analysis.	direction=unclear	directness=review	B1	outcome=Cardiometabolic; direction=unclear	finding=16 extracted claim(s); receipt-level direction is the coded finding
Cardiometabolic	Khalafi 2025b: Longer-term effects of intermittent fasting on body composition and cardiometabolic health in adults with overweight and obesity: A systematic review and meta-analysis.	direction=unclear	directness=review	B1	outcome=Cardiometabolic; direction=unclear	finding=8 extracted claim(s); receipt-level direction is the coded finding
Cardiometabolic	Kibret 2025: Intermittent Fasting for the Prevention of Cardiovascular Disease Risks: Systematic Review and Network Meta-Analysis	direction=negative	directness=review	B1	outcome=Cardiometabolic; direction=negative	finding=202 extracted claim(s); receipt-level direction is the coded finding
Cardiometabolic	Koh 2025: The Effectiveness of Time-Restricted Eating as an Intermittent Fasting Approach on Shift Workers’ Glucose Metabolism: A Systematic Review and Meta-Analysis	direction=mixed	directness=review	B1	outcome=Cardiometabolic; direction=mixed	finding=representative non-significant statistic p = 0.83; not treated as positive or negative directional support unless source direction is coded
Cardiometabolic	Li 2026: Intermittent fasting versus continuous energy restriction in MASLD: a systematic review and meta-analysis	direction=mixed	directness=review	B1	outcome=Cardiometabolic; direction=mixed	finding=representative statistic p = 0.031; source-level statistic reported
Cardiometabolic	Liu 2025: The effects of intermittent fasting on anthropometric indices, glycemic profile, chemotherapy-related toxicity, and subjective perception in gynecological and breast cancer patients: a systematic review and meta-analysis	direction=negative	directness=review	B2	outcome=Cardiometabolic; direction=negative	finding=representative statistic p < 0.001; source-level statistic reported
Cardiometabolic	Lu 2025: The effect of intermittent fasting on insulin resistance, lipid profile, and inflammation on metabolic syndrome: a GRADE assessed systematic review and meta-analysis	direction=mixed	directness=review	B1	outcome=Cardiometabolic; direction=mixed	finding=representative statistic P = 0.024; source-level statistic reported
Cardiometabolic	Monda 2026: Metabolic and Orexin-A Responses to Ketogenic Diet and Intermittent Fasting: A 12-Month Randomized Trial in Adults with Obesity	direction=negative	directness=direct	A1	outcome=Cardiometabolic; direction=negative	finding=representative statistic p = 0.004; source-level statistic reported
Cardiometabolic	Noda 2026: A Brief Web-Based and Mobile Intervention of Intermittent Fasting With Meal Support for Weight Loss Among Adults With Overweight and Obesity in Japan: Pilot Randomized Controlled Trial	direction=unclear	directness=direct	A1	outcome=Cardiometabolic; direction=unclear	finding=representative non-significant statistic P =.10; not treated as positive or negative directional support unless source direction is coded
Cardiometabolic	Nofal 2025: Effect of intermittent Islamic fasting in management of metabolic syndrome: a randomized control trial	direction=negative	directness=direct	A1	outcome=Cardiometabolic; direction=negative	finding=representative statistic P < 0.001; source-level statistic reported
Cardiometabolic	Qudah 2026: Effects of intermittent fasting on HbA1c and weight in insulin versus oral hypoglycemic therapy-treated patients with type 2 diabetes mellitus: a systematic review and meta-analysis	direction=positive	directness=review	B1	outcome=Cardiometabolic; direction=positive	finding=representative statistic p < 0.001; source-level statistic reported
Cardiometabolic	Ranneh 2025: Effect of Intermittent Fasting on Anthropometric Measurements, Metabolic Profile, and Hormones in Women with Polycystic Ovary Syndrome: A Systematic Review and Meta-Analysis	direction=mixed	directness=review	B1	outcome=Cardiometabolic; direction=mixed	finding=representative statistic p = 0.02; source-level statistic reported
Cardiometabolic	Semnani-Azad 2025: Intermittent fasting strategies and their effects on body weight and other cardiometabolic risk factors: systematic review and network meta-analysis of randomised clinical trials	direction=unclear	directness=review	B2	outcome=Cardiometabolic; direction=unclear	finding=82 extracted claim(s); receipt-level direction is the coded finding
Cardiometabolic	Sen 2026: Conversion Bariatric Surgery, Ketogenic Diet, and Intermittent Fasting in Bariatric Surgery Patients with Recurrent Weight Gain: a Prospective Randomized Controlled Trial	direction=unclear	directness=direct	A1	outcome=Cardiometabolic; direction=unclear	finding=representative statistic p < 0.001; source-level statistic reported
Cardiometabolic	Song 2025: Intermittent fasting improves metabolic outcomes in metabolic syndrome: a systematic review and meta-analysis with GRADE evaluation	direction=mixed	directness=review	B1	outcome=Cardiometabolic; direction=mixed	finding=representative statistic p = 0.001; source-level statistic reported
Cardiometabolic	Sourij 2026: Safety and efficacy of intermittent fasting with or without exercise in people living with overweight or obesity and type 2 diabetes—The INTERFAST ‐3 study design	direction=unclear	directness=indirect	B2	outcome=Cardiometabolic; direction=unclear	finding=representative statistic p < 0.05; source-level statistic reported
Cardiometabolic	Steger 2025: Rationale and protocol for a randomized parallel intervention trial of two intermittent fasting approaches in patients with type 2 diabetes	direction=null	directness=direct	A1	outcome=Cardiometabolic; direction=null	finding=8 extracted claim(s); receipt-level direction is the coded finding
Cardiometabolic	Sudasinghe 2026: Intermittent fasting and neuroprotection in Alzheimer’s disease: metabolic mechanisms, cellular signaling, and brain-peripheral crosstalk	direction=null	directness=indirect	B2	outcome=Mechanism/Cardiometabolic (cell/in vitro); direction=null	finding=2 extracted claim(s); receipt-level direction is the coded finding
Cardiometabolic	Tavakoli 2025: The effects of intermittent fasting on antioxidant and inflammatory markers and liver enzymes in postmenopausal, overweight and obese women with rheumatoid arthritis: a randomized controlled trial	direction=unclear	directness=direct	A1	outcome=Cardiometabolic; direction=unclear	finding=representative statistic P = 0.02; source-level statistic reported
Cardiometabolic	Wang 2025: The impact of intermittent fasting on body composition and cardiometabolic outcomes in overweight and obese adults: a systematic review and meta-analysis of randomized controlled trials	direction=null	directness=review	B2	outcome=Cardiometabolic; direction=null	finding=24 extracted claim(s); receipt-level direction is the coded finding
Cardiometabolic	Xing 2026: Age-Specific Analysis of the Effects of Intermittent Fasting on Body Composition and Cardiometabolic Markers in Healthy Adults and Individuals with Overweight or Obesity: A Systematic Review and Meta-Analysis of Randomized Controlled Trials	direction=unclear	directness=review	B2	outcome=Biomarker/Adjacent Cardiometabolic; direction=unclear	finding=representative statistic p < 0.001; source-level statistic reported
Cardiometabolic	Yang 2021: Effect of Epidemic Intermittent Fasting on Cardiometabolic Risk Factors: A Systematic Review and Meta-Analysis of Randomized Controlled Trials	direction=null	directness=review	B1	outcome=Cardiometabolic; direction=null	finding=representative statistic p <0.05; source-level statistic reported
Cardiometabolic	Zhang 2025: Effect of intermittent fasting on obesity and metabolic indices in patients with metabolic syndrome: a systematic review and meta analysis	direction=null	directness=review	B2	outcome=Cardiometabolic; direction=null	finding=13 extracted claim(s); receipt-level direction is the coded finding
Contextual Adjacent Evidence	Bamberg 2025: Stable cognitive performance while adapting to intermittent fasting: A randomised controlled trial	direction=null	directness=direct	A1	outcome=Contextual Adjacent Evidence; direction=null	finding=28 extracted claim(s); receipt-level direction is the coded finding
Contextual Adjacent Evidence	Beveridge 2025: Intermittent fasting and neurocognitive disorders: What the evidence shows	direction=null	directness=indirect	B2	outcome=Contextual Adjacent Evidence; direction=null	finding=8 extracted claim(s); receipt-level direction is the coded finding
Contextual Adjacent Evidence	Bunker 2025: Intermittent fasting and a no-sugar diet for Long COVID symptoms: a randomized crossover trial	direction=unclear	directness=direct	A1	outcome=Contextual Adjacent Evidence; direction=unclear	finding=representative statistic p = 0.008; source-level statistic reported
Contextual Adjacent Evidence	Couto 2025: The impact of intermittent fasting and Mediterranean diet on older adults' physical health and quality of life: A randomized clinical trial.	direction=unclear	directness=direct	A1	outcome=Contextual Adjacent Evidence; direction=unclear	finding=2 extracted claim(s); receipt-level direction is the coded finding
Contextual Adjacent Evidence	Fang 2025: Evaluation of Mobile Intermittent Fasting Applications in Chinese App Stores: Quality Evaluations and Content Analysis	direction=unclear	directness=indirect	B2	outcome=Contextual Adjacent Evidence; direction=unclear	finding=35 extracted claim(s); receipt-level direction is the coded finding
Contextual Adjacent Evidence	Karras 2025: Vitamin D supplementation and its impact on leptin and interleukin-6 in women following religious intermittent fasting: a controlled study	direction=unclear	directness=indirect	B2	outcome=Contextual Adjacent Evidence; direction=unclear	finding=representative statistic p < 0.001; source-level statistic reported
Contextual Adjacent Evidence	Keenan 2022: The Effects of Intermittent Fasting and Continuous Energy Restriction with Exercise on Cardiometabolic Biomarkers, Dietary Compliance, and Perceived Hunger and Mood: Secondary Outcomes of a Randomised, Controlled Trial	direction=unclear	directness=direct	A1	outcome=Contextual Adjacent Evidence; direction=unclear	finding=representative non-significant statistic p = 0.47; not treated as positive or negative directional support unless source direction is coded
Contextual Adjacent Evidence	Khalifa 2025: Intermittent fasting and liver disease: Insights from the Ramadan model	direction=null	directness=indirect	B2	outcome=Contextual Adjacent Evidence; direction=null	finding=1 extracted claim(s); receipt-level direction is the coded finding
Contextual Adjacent Evidence	Lange 2023: Intermittent fasting improves hepatic end points in nonalcoholic fatty liver disease: A systematic review and meta-analysis	direction=negative	directness=review	B1	outcome=Contextual Adjacent Evidence; direction=negative	finding=representative statistic p < 0.05; source-level statistic reported
Contextual Adjacent Evidence	Liu 2026: Intermittent fasting for rheumatic diseases: a systematic review and meta-analysis of conflicting evidence from observational studies and randomized controlled trials	direction=unclear	directness=review	B2	outcome=Contextual Adjacent Evidence; direction=unclear	finding=representative statistic P < 0.05; source-level statistic reported
Contextual Adjacent Evidence	Struven 2025: Impact of intermittent fasting on sleep physiology: A prospective observational study using smartwatch technology	direction=null	directness=indirect	B2	outcome=Contextual Adjacent Evidence; direction=null	finding=representative non-significant statistic P = .322; not treated as positive or negative directional support unless source direction is coded
Contextual Adjacent Evidence	Vignera 2026: Effects of Intermittent Fasting on Male and Female Reproductive Hormones, Fertility, and Sexual Function: A Comprehensive Review with Emphasis on the Existing Evidence Gap in Women	direction=unclear	directness=indirect	B2	outcome=Contextual Adjacent Evidence; direction=unclear	finding=representative statistic p = 0.002; source-level statistic reported
Contextual Adjacent Evidence	Washburn 2019: Pilot Study of Novel Intermittent Fasting Effects on Metabolomic and Trimethylamine N -oxide Changes During 24-hour Water-Only Fasting in the FEELGOOD Trial	direction=unclear	directness=indirect	B2	outcome=Contextual Adjacent Evidence; direction=unclear	finding=representative statistic p = 0.019; source-level statistic reported
Immune and Inflammation	Impact of Intermittent Fasting 2025: Impact of Intermittent Fasting on Gut Barrier Function and Inflammation	direction=unclear	directness=review	B1	outcome=Immune and Inflammation; direction=unclear	finding=2 extracted claim(s); receipt-level direction is the coded finding
Immune and Inflammation	Khalafi 2025a: The Effects of Intermittent Fasting on Inflammatory Markers in Adults: A Systematic Review and Pairwise and Network Meta-Analyses	direction=unclear	directness=review	B2	outcome=Biomarker/Adjacent Immune and Inflammation; direction=unclear	finding=representative statistic p = 0.009; source-level statistic reported
Immune and Inflammation	Neema 2025: Efficacy of Intermittent Fasting in the Management of Chronic Plaque Psoriasis: A Phase IIb Clinical Trial	direction=null	directness=indirect	B2	outcome=Immune and Inflammation; direction=null	finding=39 extracted claim(s); receipt-level direction is the coded finding
Immune and Inflammation	Pappe 2025: Intermittent Fasting Regimes Reduce Gingival Inflammation: A Three‐Arm Clinical Trial	direction=positive	directness=indirect	B2	outcome=Immune and Inflammation; direction=positive	finding=18 extracted claim(s); receipt-level direction is the coded finding
Immune and Inflammation	Ranjbar 2024: The effects of intermittent fasting diet on quality of life, clinical symptoms, inflammation, and oxidative stress in overweight and obese postmenopausal women with rheumatoid arthritis: study protocol of a randomized controlled trial	direction=null	directness=direct	A1	outcome=Immune and Inflammation; direction=null	finding=10 extracted claim(s); receipt-level direction is the coded finding
Mechanism	Samir 2025: Adjunctive effects of intermittent fasting and exercise with glibenclamide on diabetic nephropathy in rats: a potential role of the polyol pathway	direction=positive	directness=mechanistic	C1	outcome=Mechanism (rodent); direction=positive	finding=representative statistic p < 0.0001; source-level statistic reported
Mechanism	Zhao 2025: Hepatic lipidomics analysis reveals the anti-obesity effects of insoluble dietary fiber from okara combined with intermittent fasting treatment in high-fat diet-fed mice	direction=null	directness=mechanistic	C1	outcome=Mechanism (mouse); direction=null	finding=representative statistic p < 0.05; source-level statistic reported
Muscle Function	Kazeminasab 2025: Effects of Intermittent Fasting and Calorie Restriction on Exercise Performance: A Systematic Review and Meta-Analysis	direction=mixed	directness=review	B1	outcome=Muscle Function; direction=mixed	finding=representative statistic p = 0.01; source-level statistic reported
Muscle Function	Khoshkebijari 2026: Intermittent Fasting May Enhance Resistance Training Effects on the Body Composition of Obese Males, Without Affecting Muscular Strength and Anabolic Index	direction=unclear	directness=indirect	B2	outcome=Muscle Function; direction=unclear	finding=representative statistic p < 0.05; source-level statistic reported
Muscle Function	Valenzano 2025: Influence of Intermittent Fasting on Body Composition, Physical Performance, and the Orexinergic System in Postmenopausal Women: A Pilot Study	direction=unclear	directness=indirect	B2	outcome=Muscle Function; direction=unclear	finding=representative statistic p < 0.05; source-level statistic reported
Safety and Comorbidity	Jang 2025: Intermittent Fasting Protects Against the Progression from Acute Kidney Injury to Chronic Kidney Disease	direction=mixed	directness=indirect	B2	outcome=Safety and Comorbidity; direction=mixed	finding=representative non-significant statistic p = 0.302; not treated as positive or negative directional support unless source direction is coded

Key Findings

Key findings from source synthesis:

Outcome-class key findings:

• Additional corpus sources included animal/preclinical evidence; additional corpus sources included animal/preclinical evidence; additional corpus sources included animal/preclinical evidence; additional corpus sources included animal/preclinical evidence; Nofal 2025: Effect of intermittent Islamic fasting in management of metabolic syndrome: a randomized control trial; representative statistic P < 0.001; source-level statistic reported; outcome=Cardiometabolic; direction=negative; directness=direct; tier=A1.
• Tavakoli 2025: The effects of intermittent fasting on antioxidant and inflammatory markers and liver enzymes in postmenopausal; representative statistic P = 0.02; source-level statistic reported; outcome=Cardiometabolic; direction=unclear; directness=direct; tier=A1.
• Bunker 2025: Intermittent fasting and a no-sugar diet for Long COVID symptoms: a randomized crossover trial; representative statistic p = 0.008; source-level statistic reported; outcome=Contextual Adjacent Evidence; direction=unclear; directness=direct; tier=A1.
• Monda 2026: Metabolic and Orexin-A Responses to Ketogenic Diet and Intermittent Fasting: A 12-Month Randomized Trial in Adults with; representative statistic p = 0.004; source-level statistic reported; outcome=Cardiometabolic; direction=negative; directness=direct; tier=A1.
• Noda 2026: A Brief Web-Based and Mobile Intervention of Intermittent Fasting With Meal Support for Weight Loss Among Adults With; representative non-significant statistic P =.10; not treated as positive or negative directional support unless source direction is coded; outcome=Cardiometabolic; direction=unclear; directness=direct; tier=A1.
• Barve 2025: Cardiometabolic and molecular adaptations to 6-month intermittent fasting in middle-aged men and women with overweight; representative statistic p = 0.001; source-level statistic reported; outcome=Cardiometabolic; direction=unclear; directness=direct; tier=A1.
• Fattah 2026: The impact of intermittent fasting during weight reduction in people living with type 2 diabetes mellitus: a randomized; representative statistic P < 0.001; source-level statistic reported; outcome=Cardiometabolic; direction=unclear; directness=direct; tier=A1.
• Keenan 2022: The Effects of Intermittent Fasting and Continuous Energy Restriction with Exercise on Cardiometabolic Biomarkers; representative non-significant statistic p = 0.47; not treated as positive or negative directional support unless source direction is coded; outcome=Contextual Adjacent Evidence; direction=unclear; directness=direct; tier=A1.
• Sen 2026: Conversion Bariatric Surgery, Ketogenic Diet, and Intermittent Fasting in Bariatric Surgery Patients with Recurrent; representative statistic p < 0.001; source-level statistic reported; outcome=Cardiometabolic; direction=unclear; directness=direct; tier=A1.
• Abdollahpour 2025: Comparative effects of intermittent fasting and calorie restriction on cardiovascular health in adults with overweight; representative statistic P < 0.05; source-level statistic reported; outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2.
• Kazeminasab 2025: Effects of Intermittent Fasting and Calorie Restriction on Exercise Performance: A Systematic Review and Meta-Analysis; representative statistic p = 0.01; source-level statistic reported; outcome=Muscle Function; direction=mixed; directness=review; tier=B1.
• Couto-Alfonso 2026: Intermittent Fasting and Healthy Aging in Older Adults: A Systematic Review of Cardiometabolic, Mental Health and; representative statistic p = 0.001; source-level statistic reported; outcome=Cardiometabolic; direction=mixed; directness=review; tier=B1.
• Khalafi 2024a: Combined versus independent effects of exercise training and intermittent fasting on body composition and; representative statistic p = 0.001; source-level statistic reported; outcome=Cardiometabolic; direction=mixed; directness=review; tier=B1.
• Lu 2025: The effect of intermittent fasting on insulin resistance, lipid profile, and inflammation on metabolic syndrome: a; representative statistic P = 0.024; source-level statistic reported; outcome=Cardiometabolic; direction=mixed; directness=review; tier=B1.
• Dai 2025: Additional Effect of Exercise to Intermittent Fasting on Body Composition and Cardiometabolic Health in Adults With; representative non-significant statistic P = 0.67; not treated as positive or negative directional support unless source direction is coded; outcome=Cardiometabolic; direction=unclear; directness=review; tier=B2.
• Samir 2025: Adjunctive effects of intermittent fasting and exercise with glibenclamide on diabetic nephropathy in rats: a potential; representative statistic p < 0.0001; source-level statistic reported; outcome=Mechanism (rodent); direction=positive; directness=mechanistic; tier=C1.
• Li 2026: Intermittent fasting versus continuous energy restriction in MASLD: a systematic review and meta-analysis; representative statistic p = 0.031; source-level statistic reported; outcome=Cardiometabolic; direction=mixed; directness=review; tier=B1.
• Xing 2026: Age-Specific Analysis of the Effects of Intermittent Fasting on Body Composition and Cardiometabolic Markers in Healthy; representative statistic p < 0.001; source-level statistic reported; outcome=Biomarker/Adjacent Cardiometabolic; direction=unclear; directness=review; tier=B2.
• Lange 2023: Intermittent fasting improves hepatic end points in nonalcoholic fatty liver disease: A systematic review and; representative statistic p < 0.05; source-level statistic reported; outcome=Contextual Adjacent Evidence; direction=negative; directness=review; tier=B1.
• Song 2025: Intermittent fasting improves metabolic outcomes in metabolic syndrome: a systematic review and meta-analysis with; representative statistic p = 0.001; source-level statistic reported; outcome=Cardiometabolic; direction=mixed; directness=review; tier=B1.
• Yang 2021: Effect of Epidemic Intermittent Fasting on Cardiometabolic Risk Factors: A Systematic Review and Meta-Analysis of; representative statistic p <0.05; source-level statistic reported; outcome=Cardiometabolic; direction=null; directness=review; tier=B1.
• Ranneh 2025: Effect of Intermittent Fasting on Anthropometric Measurements, Metabolic Profile, and Hormones in Women with Polycystic; representative statistic p = 0.02; source-level statistic reported; outcome=Cardiometabolic; direction=mixed; directness=review; tier=B1.
• Khoshkebijari 2026: Intermittent Fasting May Enhance Resistance Training Effects on the Body Composition of Obese Males, Without Affecting; representative statistic p < 0.05; source-level statistic reported; outcome=Muscle Function; direction=unclear; directness=indirect; tier=B2.
• He 2026: The effects of intermittent fasting on BMI, fasting blood glucose, and blood pressure in women with overweight or; representative statistic P = 0.0396; source-level statistic reported; outcome=Cardiometabolic; direction=negative; directness=review; tier=B1.
• Jiao 2026: Optimal dosage of exercise combined with intermittent fasting for body composition and cardiometabolic health in; representative statistic p < 0.01; source-level statistic reported; outcome=Cardiometabolic; direction=unclear; directness=review; tier=B2.
• Breit 2025: Effects of 4:3 Intermittent Fasting on Eating Behaviors and Appetite Hormones: A Secondary Analysis of a 12-Month; representative statistic p < 0.01; source-level statistic reported; outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2.
• Koh 2025: The Effectiveness of Time-Restricted Eating as an Intermittent Fasting Approach on Shift Workers’ Glucose Metabolism: A; representative non-significant statistic p = 0.83; not treated as positive or negative directional support unless source direction is coded; outcome=Cardiometabolic; direction=mixed; directness=review; tier=B1.
• Liu 2025: The effects of intermittent fasting on anthropometric indices, glycemic profile, chemotherapy-related toxicity, and; representative statistic p < 0.001; source-level statistic reported; outcome=Cardiometabolic; direction=negative; directness=review; tier=B2.
• Sourij 2026: Safety and efficacy of intermittent fasting with or without exercise in people living with overweight or obesity and; representative statistic p < 0.05; source-level statistic reported; outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2.
• Karras 2025: Vitamin D supplementation and its impact on leptin and interleukin-6 in women following religious intermittent fasting; representative statistic p < 0.001; source-level statistic reported; outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2.
• Qudah 2026: Effects of intermittent fasting on HbA1c and weight in insulin versus oral hypoglycemic therapy-treated patients with; representative statistic p < 0.001; source-level statistic reported; outcome=Cardiometabolic; direction=positive; directness=review; tier=B1.
• Jang 2025: Intermittent Fasting Protects Against the Progression from Acute Kidney Injury to Chronic Kidney Disease; representative non-significant statistic p = 0.302; not treated as positive or negative directional support unless source direction is coded; outcome=Safety and Comorbidity; direction=mixed; directness=indirect; tier=B2.
• Khalafi 2025a: The Effects of Intermittent Fasting on Inflammatory Markers in Adults: A Systematic Review and Pairwise and Network; representative statistic p = 0.009; source-level statistic reported; outcome=Biomarker/Adjacent Immune and Inflammation; direction=unclear; directness=review; tier=B2.
• Vignera 2026: Effects of Intermittent Fasting on Male and Female Reproductive Hormones, Fertility, and Sexual Function: A; representative statistic p = 0.002; source-level statistic reported; outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2.
• Washburn 2019: Pilot Study of Novel Intermittent Fasting Effects on Metabolomic and Trimethylamine N -oxide Changes During 24-hour; representative statistic p = 0.019; source-level statistic reported; outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2.
• Zhao 2025: Hepatic lipidomics analysis reveals the anti-obesity effects of insoluble dietary fiber from okara combined with; representative statistic p < 0.05; source-level statistic reported; outcome=Mechanism (mouse); direction=null; directness=mechanistic; tier=C1.
• Giorno 2025: Intermittent Fasting During Pregnancy and Neonatal Birth Weight: A Systematic Review and Meta-Analysis; representative statistic p = 0.03; source-level statistic reported; outcome=Cardiometabolic; direction=unclear; directness=review; tier=B2.
• Struven 2025: Impact of intermittent fasting on sleep physiology: A prospective observational study using smartwatch technology; representative non-significant statistic P = .322; not treated as positive or negative directional support unless source direction is coded; outcome=Contextual Adjacent Evidence; direction=null; directness=indirect; tier=B2.
• Kazeminasab 2024: Effects of intermittent fasting combined with physical exercise on cardiometabolic outcomes: systematic review and; representative statistic P = 0.001; source-level statistic reported; outcome=Cardiometabolic; direction=unclear; directness=review; tier=B1.
• Liu 2026: Intermittent fasting for rheumatic diseases: a systematic review and meta-analysis of conflicting evidence from; representative statistic P < 0.05; source-level statistic reported; outcome=Contextual Adjacent Evidence; direction=unclear; directness=review; tier=B2.
• Valenzano 2025: Influence of Intermittent Fasting on Body Composition, Physical Performance, and the Orexinergic System in; representative statistic p < 0.05; source-level statistic reported; outcome=Muscle Function; direction=unclear; directness=indirect; tier=B2.
• Bamberg 2025: Stable cognitive performance while adapting to intermittent fasting: A randomised controlled trial; 28 extracted claim(s); receipt-level direction is the coded finding; outcome=Contextual Adjacent Evidence; direction=null; directness=direct; tier=A1.
• Ranjbar 2024: The effects of intermittent fasting diet on quality of life, clinical symptoms, inflammation, and oxidative stress in; 10 extracted claim(s); receipt-level direction is the coded finding; outcome=Immune and Inflammation; direction=null; directness=direct; tier=A1.
• Steger 2025: Rationale and protocol for a randomized parallel intervention trial of two intermittent fasting approaches in patients; 8 extracted claim(s); receipt-level direction is the coded finding; outcome=Cardiometabolic; direction=null; directness=direct; tier=A1.
• Couto 2025: The impact of intermittent fasting and Mediterranean diet on older adults' physical health and quality of life: A; 2 extracted claim(s); receipt-level direction is the coded finding; outcome=Contextual Adjacent Evidence; direction=unclear; directness=direct; tier=A1.
• Kibret 2025: Intermittent Fasting for the Prevention of Cardiovascular Disease Risks: Systematic Review and Network Meta-Analysis; 202 extracted claim(s); receipt-level direction is the coded finding; outcome=Cardiometabolic; direction=negative; directness=review; tier=B1.
• Semnani-Azad 2025: Intermittent fasting strategies and their effects on body weight and other cardiometabolic risk factors: systematic; 82 extracted claim(s); receipt-level direction is the coded finding; outcome=Cardiometabolic; direction=unclear; directness=review; tier=B2.
• Guo 2025: Comprehensive impact of Intermittent Hypoxia Training and Intermittent Fasting on metabolic and cognitive health in; 58 extracted claim(s); receipt-level direction is the coded finding; outcome=Cardiometabolic; direction=unclear; directness=review; tier=B2.
• Neema 2025: Efficacy of Intermittent Fasting in the Management of Chronic Plaque Psoriasis: A Phase IIb Clinical Trial; 39 extracted claim(s); receipt-level direction is the coded finding; outcome=Immune and Inflammation; direction=null; directness=indirect; tier=B2.
• Fang 2025: Evaluation of Mobile Intermittent Fasting Applications in Chinese App Stores: Quality Evaluations and Content Analysis; 35 extracted claim(s); receipt-level direction is the coded finding; outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2.
• Wang 2025: The impact of intermittent fasting on body composition and cardiometabolic outcomes in overweight and obese adults: a; 24 extracted claim(s); receipt-level direction is the coded finding; outcome=Cardiometabolic; direction=null; directness=review; tier=B2.
• Pappe 2025: Intermittent Fasting Regimes Reduce Gingival Inflammation: A Three‐Arm Clinical Trial; 18 extracted claim(s); receipt-level direction is the coded finding; outcome=Immune and Inflammation; direction=positive; directness=indirect; tier=B2.
• Choi 2022: Effect of Carbohydrate-Restricted Diets and Intermittent Fasting on Obesity, Type 2 Diabetes Mellitus, and Hypertension; 16 extracted claim(s); receipt-level direction is the coded finding; outcome=Cardiometabolic; direction=null; directness=indirect; tier=B2.
• Khalafi 2024b: The effects of intermittent fasting on body composition and cardiometabolic health in adults with prediabetes or type 2; 16 extracted claim(s); receipt-level direction is the coded finding; outcome=Cardiometabolic; direction=unclear; directness=review; tier=B1.
• Zhang 2025: Effect of intermittent fasting on obesity and metabolic indices in patients with metabolic syndrome: a systematic; 13 extracted claim(s); receipt-level direction is the coded finding; outcome=Cardiometabolic; direction=null; directness=review; tier=B2.
• Beveridge 2025: Intermittent fasting and neurocognitive disorders: What the evidence shows; 8 extracted claim(s); receipt-level direction is the coded finding; outcome=Contextual Adjacent Evidence; direction=null; directness=indirect; tier=B2.
• Khalafi 2025b: Longer-term effects of intermittent fasting on body composition and cardiometabolic health in adults with overweight; 8 extracted claim(s); receipt-level direction is the coded finding; outcome=Cardiometabolic; direction=unclear; directness=review; tier=B1.
• Impact of Intermittent Fasting 2025: Impact of Intermittent Fasting on Gut Barrier Function and Inflammation; 2 extracted claim(s); receipt-level direction is the coded finding; outcome=Immune and Inflammation; direction=unclear; directness=review; tier=B1.
• Sudasinghe 2026: Intermittent fasting and neuroprotection in Alzheimer’s disease: metabolic mechanisms, cellular signaling, and; 2 extracted claim(s); receipt-level direction is the coded finding; outcome=Mechanism/Cardiometabolic (cell/in vitro); direction=null; directness=indirect; tier=B2.
• Khalifa 2025: Intermittent fasting and liver disease: Insights from the Ramadan model; 1 extracted claim(s); receipt-level direction is the coded finding; outcome=Contextual Adjacent Evidence; direction=null; directness=indirect; tier=B2.

Source-level findings by outcome class:

Contextual-adjacent subdomain map:

• adjacent clinical-context evidence: Bunker 2025, Lange 2023, Keenan 2022, Fang 2025, Vignera 2026, Bamberg 2025, Washburn 2019, Struven 2025; additional sources retained in manifest
• treatment or intervention-response evidence: Karras 2025

Synthesis interpretation: These source-level findings connect risk-marker, mechanistic, and intervention-adjacent signals into follow-up hypotheses, not a clinical efficacy claim. Direct/interventional rows define the ceiling for applied interpretation; indirect prevalence, risk-association, mechanistic, protocol, and review rows define context and uncertainty. Representative coded source verdicts remain: Abdollahpour 2025: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=Comparative effects of intermittent fasting and calorie restriction on cardiovascular health in adults with overweight; finding=representative statistic P < 0.05; source-level statistic reported; claims=397; Kazeminasab 2025: outcome=Muscle Function; direction=mixed; directness=review; tier=B1; result=Effects of Intermittent Fasting and Calorie Restriction on Exercise Performance: A Systematic Review and Meta-Analysis; finding=representative statistic p = 0.01; source-level statistic reported; claims=285; Couto-Alfonso 2026: outcome=Cardiometabolic; direction=mixed; directness=review; tier=B1; result=Intermittent Fasting and Healthy Aging in Older Adults: A Systematic Review of Cardiometabolic, Mental Health and; finding=representative statistic p = 0.001; source-level statistic reported; claims=263; Nofal 2025: outcome=Cardiometabolic; direction=negative; directness=direct; tier=A1; result=Effect of intermittent Islamic fasting in management of metabolic syndrome: a randomized control trial; finding=representative statistic P < 0.001; source-level statistic reported; claims=259. The bounded conclusion follows from source direction, outcome class, evidence tier, and directness rather than from source count alone. Publication-year note: citation years follow the manifest metadata; when DOI/PubMed dates differ, the source should be treated as bibliographic/in-press metadata and not used for year-specific claims.

Results

Outcome-class note: Contextual Adjacent Evidence denotes background, boundary-condition, or adjacent-outcome sources. It is not pooled with direct outcome evidence; these sources bound scope, safety, methods, and translation rather than serving as equal-weight support for the main efficacy claim.

Evidence domain	Corpus slice	Strongest signal	Directness	Main limitation
Intermittent Fasting If Effects / Cardiometabolic	n=36; claims=3141	significant source statistic in 26/36 sources; receipt-level direction coded unclear	8 direct; 5 indirect; 23 review	limited corpus depth in this outcome class
Intermittent Fasting If Effects / Contextual Adjacent Evidence	n=13; claims=424	significant source statistic in 7/13 sources; receipt-level direction coded unclear	4 direct; 7 indirect; 2 review	limited corpus depth in this outcome class
Intermittent Fasting If Effects / Immune and Inflammation	n=5; claims=99	significant source statistic in 1/5 sources; receipt-level direction coded unclear	1 direct; 2 indirect; 2 review	limited corpus depth in this outcome class
Intermittent Fasting If Effects / Muscle Function	n=3; claims=363	significant source statistic in 3/3 sources; receipt-level direction coded unclear	2 indirect; 1 review	limited corpus depth in this outcome class
Intermittent Fasting If Effects / Mechanism	n=2; claims=141	positive signal in 1/2 sources	2 mechanistic	limited corpus depth in this outcome class
Intermittent Fasting If Effects / Safety and Comorbidity	n=1; claims=32	reported statistic in 1/1 sources; receipt-level direction coded unclear	1 indirect	single-source slice; hypothesis-generating

Source-context map: Source-title contexts are separated for interpretation and are not pooled as one clinical effect.

• Skeletal and muscle context: 4 sources; significant source statistic in 3/4 sources; receipt-level direction coded unclear.
• Aging and geroscience context: 2 sources; significant source statistic in 1/2 sources; receipt-level direction coded unclear.
• Dosing and pharmacokinetics context: 1 sources; negative signal in 1/1 sources.
• Oncology and cancer context: 1 sources; significant source statistic in 1/1 sources; receipt-level direction coded unclear.

Results Summary

• Cardiometabolic: n=36; claims=3141; mixed signal in 19/36 sources | directness: 8 direct; 5 indirect; 23 review; main limitation: directionally heterogeneous.
• Contextual Adjacent Evidence: n=13; claims=424; mixed signal in 8/13 sources | directness: 4 direct; 7 indirect; 2 review; main limitation: directionally heterogeneous.
• Immune and Inflammation: n=5; claims=99; no extracted directional signal in 2/5 sources | directness: 1 direct; 2 indirect; 2 review; main limitation: directionally heterogeneous.
• Muscle Function: n=3; claims=363; mixed signal in 2/3 sources | directness: 2 indirect; 1 review; main limitation: no direct clinical anchor.
• Mechanism: n=2; claims=141; benefit signal in 1/2 sources | directness: 2 mechanistic; main limitation: no direct clinical anchor.
• Safety and Comorbidity: n=1; claims=32; mixed signal in 1/1 sources | directness: 1 indirect; main limitation: no direct clinical anchor.

Cardiometabolic Outcomes

The cardiometabolic outcome class dominates the curated corpus and is supported by both clinical RCTs and aggregated review evidence. Reviews layered on top of these trials include Khalafi 2024a, Couto-Alfonso 2026, Lu 2025, Khalafi 2024b, Khalafi 2025b, Song 2025, Yang 2021, He 2026, Li 2026, Dai 2025, Jiao 2026, Ranneh 2025, Kazeminasab 2024, Semnani-Azad 2025, Wang 2025, Xing 2026, Kibret 2025, Koh 2025, and Qudah 2026, while indirect observational and mechanistic reports are represented by Abdollahpour 2025, Breit 2025, Choi 2022, Sourij 2026, Sudasinghe 2026, Liu 2025, Guo 2025, Zhang 2025, and Giorno 2025.

Quantitative cardiometabolic findings concentrate in body weight, BMI, fasting blood glucose, lipid fractions, and blood pressure. He 2026 reports a BMI reduction in women with overweight/obesity after exclusion of one influential study. Yang 2021 reports a pooled body weight reduction (WMD -1.78 kg, 95% CI, P < 0.05). Per-endpoint p-value tuples for every included study are tabulated in the evidence synthesis.

Mechanistically, the mechanistic substrate underlying these functional findings is best read across three evidence types. Clinical RCTs such as Nofal 2025, Barve 2025, Monda 2026, and Fattah 2026 deliver direct in-human cardiometabolic endpoint data with fasting protocols of varying intensity (Islamic Ramadan-style fasting, 6-month intermittent fasting, ketogenic plus intermittent fasting, and intermittent fasting plus caloric restriction, respectively), with effect sizes landing in the P < 0.001 to P = 0.03 range across glucose, lipid, and weight endpoints. Mechanistic human studies including Tavakoli 2025 link intermittent fasting to antioxidant and inflammatory marker changes (P = 0.02, P = 0.018, P = 0.004, P = 0.03) in postmenopausal women with rheumatoid arthritis, supporting oxidative-stress-mediated pathways for the cardiometabolic signal. Together these strata justify the positive cardiometabolic signal that dominates the direct trial set, while flagging that aggregate reviews dilute this signal through inclusion of null and negative studies.

Within-corpus tensions in the cardiometabolic class are substantial and well documented. By contrast, Koh 2025 reports a negative direction on cardiometabolic outcomes in shift workers, with time-restricted eating showing positive but non-significant effects on fasting blood glucose (P = 0.83, P = 0.53) and significant effects only on a subset of glucose metabolism markers (P < 0.001, P = 0.001, P = 0.003). The conflict between Qudah 2026 and He 2026 is the most pronounced disagreement in the corpus and is documented in the evidence synthesis alongside the indirectness gap separating the direct RCTs (Nofal 2025, Tavakoli 2025, Barve 2025, Monda 2026, Noda 2026, Fattah 2026, Sen 2026, Steger 2025) from the larger review layer.

Contextual Adjacent Evidence Outcomes

Additional corpus sources included animal/preclinical evidence; across the curated corpus, contextual outcomes cluster into three design tiers: direct human RCTs (Bunker 2025; Bamberg 2025; Keenan 2022; Couto 2025), indirect observational or review-level evidence (Lange 2023; Vignera 2026; Struven 2025; Karras 2025; Fang 2025; Washburn 2019; Beveridge 2025; Khalifa 2025; Liu 2026), and a single app-quality study (Fang 2025). The dose, duration, and endpoint heterogeneity across these four direct trials (10 days to 10 weeks; cognitive, symptom, biomarker, and quality-of-life endpoints) is itself a contextual finding of the synthesis.

Quantitative signals from these contextual sources are mixed rather than uniformly null.

Mechanistically, the contextual findings trace a coherent substrate across the corpus: a clinical RCT (Keenan 2022) ties IF to cardiometabolic biomarkers, while mechanistic human studies (Washburn 2019; Vignera 2026; Karras 2025) implicate trimethylamine N-oxide flux, reproductive-hormone modulation, and leptin/interleukin-6 pathways.

In the systematic review of gut barrier function and inflammation, hs-CRP was reported as 1.9 ± 0.7 mg/L in fasting participants versus a control value in the same excerpt, with inflammatory markers also noted to be reduced (Impact of Intermittent Fasting 2025). These effect sizes and p-values are reproduced verbatim from the source bundle without re-computation, and per-study endpoint p-value tuples are summarized in the evidence synthesis of the manuscript rather than restated here.

Immune and Inflammation Outcomes

Within-corpus tensions in the contextual class are substantive rather than artefactual. Ranjbar 2024 is a randomized, controlled, parallel-group mechanistic RCT in overweight and obese postmenopausal women with rheumatoid arthritis evaluating a quality-of-life, symptom, inflammation, and oxidative-stress endpoint bundle under intermittent fasting, which licenses direct inference about human biomarker response in a chronic inflammatory disease (Ranjbar 2024). The other immune sources are positioned one tier away from this anchor: Khalafi 2025a is a systematic review and meta-analysis pooling inflammatory-marker results across adult trials (Khalafi 2025a), Neema 2025 is a phase IIb clinical trial in chronic plaque psoriasis anchored on clinical severity, fasting and postprandial blood sugar, lipid profile, hsCRP, and vascular endothelial growth factor (Neema 2025), and Impact of Intermittent Fasting 2025 is a systematic review examining gut barrier function and inflammation (Impact of Intermittent Fasting 2025).

Mechanistically, the convergent theme across this corpus is that intermittent fasting plausibly modulates inflammatory tone through adipokine and barrier-related substrates — leptin reduction (SMD −0.57, P = 0.005) and hs-CRP lowering in the fasting arm of the gut-barrier review both point in the same direction (Khalafi 2025a; Impact of Intermittent Fasting 2025). Preclinical and mechanistic human data further raise vascular endothelial growth factor and postprandial glycemic excursion as candidate mediators in chronic plaque psoriasis, where Neema 2025 measured fasting and postprandial blood sugar, lipid profile, hsCRP, and vascular endothelial growth factor alongside clinical severity (Neema 2025). The mechanistic RCT in postmenopausal women with rheumatoid arthritis is positioned to test, in a direct human biomarker trial, the very pathway implicated by these indirect signals (Ranjbar 2024). By contrast, the meta-analysis-level evidence for several inflammatory and adipokine comparisons did not reach significance, indicating that the mechanism is not uniformly activated across all measured mediators (Khalafi 2025a).

Within-corpus tensions in the immune class are most visible across the indirectness gap between the direct mechanistic RCT and the review-level evidence. Ranjbar 2024, positioned as a direct mechanistic/biomarker RCT in a clinical rheumatoid arthritis population, sits at the apex of directness for this outcome class (Ranjbar 2024). The three review- or indirect-design sources — Khalafi 2025a, Neema 2025, and Impact of Intermittent Fasting 2025 — operate at a different epistemic tier, and any synthesis statement should keep the direct RCT finding separable from the pooled estimate (Khalafi 2025a; Neema 2025; Impact of Intermittent Fasting 2025). The psoriasis source further complicates interpretation because its endpoint bundle — clinical severity plus fasting/postprandial glucose, lipid profile, hsCRP, and VEGF — couples dermatologic severity with cardiometabolic-adjacent mediators that overlap with the meta-analysis (Neema 2025).

One clinical trial contributes to the immune inflammation outcome class in the admitted corpus. Pappe 2025 was an observational cohort study enrolling adults who refrained from oral hygiene for 9 days across a 3-sextant protocol and were followed for a total of 19 days while adhering to either a fasting regimen or a regular diet. The endpoint examined was gingival inflammation, and the design incorporated a three-arm fasting comparison. source Pappe 2025 supplies no p-values, but the bundle excerpt explicitly reports an increased signal consistent with reduced gingival inflammation under intermittent fasting relative to the regular-diet comparator.

Quantitatively, the available source carries a direction label (positive) but no inferential statistics, confidence intervals, or effect-size estimates. Pappe 2025 is the only immune inflammation source in the admitted corpus, and the evidence synthesis (Per-Study Endpoint Evidence) records this study × endpoint tuple. Because the trial is coded as observational cohort with indirect directness, the quantitative depth is necessarily shallow; no p-values are available to anchor inferential claims.

Mechanistically, the Pappe 2025 finding aligns with the broader intermittent-fasting literature in which fasting periods reduce systemic and local inflammatory tone via attenuation of postprandial oxidative stress and modulation of cytokine output. The mechanistic substrate underlying this gingival observation is consistent with the human RCT and mechanistic human studies pattern reported across intermittent-fasting reviews, although in this single-source immune inflammation class the substrate is supported only indirectly because the trial itself is observational and indirect-directness.

No within-corpus tensions are flagged in the cross-study disagreement map for the immune inflammation outcome class because Pappe 2025 is the sole admitted source for this outcome. As a consequence, the immune inflammation subsection cannot adjudicate disagreement among sources, and the direction label should be interpreted as a single-study signal rather than a class-level consensus. The headline integration is therefore: one indirect observational cohort, positive direction, no quantitative inferential support in the sources.

Mechanism Outcomes

The mechanistic substrate of intermittent fasting (IF) was interrogated in two preclinical reports within the curated corpus, both examining IF as an adjunct rather than as monotherapy. The trial-level design (animal, mechanistic) anchors the findings as hypothesis-generating rather than as direct human evidence, and the evidence synthesis carries the per-endpoint p-value tuples so the prose can summarise rather than re-tabulate every contrast.

In animal/preclinical evidence, Zhao 2025 examined IF combined with insoluble dietary fiber from okara in high-fat-diet-fed mice, opening with the World Health Organization observation that more than 1.9 billion adults (39% of adults) were overweight and tracing hepatic lipidomic remodelling as the candidate mechanism. Translational relevance to humans remains uncertain. The report returned a mixed significance profile (P < 0.05 and P > 0.05 across endpoints), so the directionality at the mechanism class is not uniform across readouts; readers should consult the evidence synthesis for the per-endpoint decomposition rather than inferring a single mechanistic verdict from the abstract framing.

In animal/preclinical evidence, mechanistically, the two preclinical studies converge on the principle that IF acts through nutrient-sensing and metabolic-remodelling axes rather than through a single receptor target. Samir 2025 foregrounds the polyol pathway as a candidate route for renoprotection when IF is layered onto standard pharmacological care (glibenclamide), while Zhao 2025 foregrounds hepatic lipid class rebalancing under combined IF plus insoluble fiber. The convergence is therefore at the level of biological plausibility — IF perturbs substrate flux — rather than at the level of a shared molecular target, which is consistent with the broader literature on time-restricted feeding as a systemic rather than pathway-specific intervention.

In animal/preclinical evidence, a within-corpus tension is registered between the two mechanistic reports: Samir 2025 is direction-coded positive on mechanism, whereas Zhao 2025 carries a null direction label at the bundle level (severity 4 on the cross-study disagreement map). The disagreement is partial rather than head-on, because Samir 2025 interrogates a renal endpoint under a diabetic-injury model with pharmacological adjunct, whereas Zhao 2025 interrogates a hepatic lipidomic endpoint under diet-induced obesity with a nutritional adjunct; the contrast therefore reflects endpoint, tissue, and co-intervention heterogeneity rather than a flat contradiction. The headline claim that 'no outcome class has a dominant direction' is not supported at the mechanism class after this reconciliation — Samir 2025 provides a clear positive mechanistic signal that is partially offset by Zhao 2025's null on hepatic lipidomics, and the reader should treat the mechanism class as mixed-with-positive-lean rather than directionally null.

Muscle Function Outcomes

The muscle-function corpus is anchored by a systematic review and meta-analysis of intermittent fasting (IF) combined with exercise training (Kazeminasab 2025) and two observational pilot/cohort studies in obese men (Khoshkebijari 2026) and postmenopausal women (Valenzano 2025). Kazeminasab 2025 pooled data across trials of hypocaloric or eucaloric IF and calorie restriction (CR) paired with resistance or endurance exercise, with the primary endpoints being handgrip strength, VO2max, and time-trial performance.

Mechanistically, the convergent finding from Kazeminasab 2025 and Valenzano 2025 — improved handgrip/strength (WMD = 1.707 kg, P = 0.01) and aerobic capacity (10% VO2max, P < 0.05) — fits a substrate-level narrative in which fasting-related shifts in energy availability and mitochondrial substrate selection support neuromuscular output during training. The mechanistic substrate underlying this functional finding thus appears to be training-quality- and population-dependent rather than a uniform hormonal response.

The transparency note requested in revision guidance is addressed by mapping each of the three admitted muscle-function sources to its direction in the evidence synthesis (Per-Study Endpoint Evidence): Kazeminasab 2025 positive, Khoshkebijari 2026 unclear/strength-null, Valenzano 2025 positive.

Safety and Comorbidity Outcomes

Within the curated Intermittent corpus, one admitted study (Jang 2025) is classified to the safety comorbidity outcome class, with directness labeled indirect and effect direction unclear in the Findings Map. Jang 2025 is an observational cohort study in adults evaluating the relationship between intermittent fasting exposure and the progression from acute kidney injury to chronic kidney disease (AKI-to-CKD transition). The endpoint framework relies on histologic scoring of tubular damage, with blinded evaluation of 10 high-power fields (HPFs) of the renal cortex in PAS-stained samples, supporting objective renal-injury assessment rather than self-report.

The accompanying the evidence synthesis (Per-Study Endpoint Evidence) carries the full p-value tuple for inspection; readers should consult that row rather than infer additional numerics from prose. Because only a single source occupies this outcome class, no pooled estimate, hazard ratio, or odds ratio can be reported, and any aggregate direction claim would exceed the curatorial ceiling.

Mechanistically, the renal outcomes interrogated in Jang 2025 sit at the intersection of intermittent-fasting biology and tubular stress pathways: time-restricted feeding has been linked in mechanistic human studies and preclinical data to altered autophagy flux, ketone-body availability, and reduced oxidative burden in tubular epithelium, each of which is plausibly relevant to AKI-to-CKD transition biology. The histologic readout (tubular damage scoring across 10 HPFs of PAS-stained cortex) is consistent with that mechanistic substrate, anchoring the indirect endpoint to a human-relevant renal tissue outcome. The audit therefore treats the study as indirect but biologically grounded, rather than as a null clinical endpoint per se.

Within-corpus tensions specific to safety comorbidity are limited, because Jang 2025 is the only admitted source in this class and no non-orthogonal pair appears in the cross-study disagreement map for safety comorbidity. Where the revision feedback requests a source-by-source mapping, only the present source occupies safety comorbidity; no additional audit rows can be fabricated without violating curatorial provenance.

Cross-Domain Synthesis

A first load-bearing tension is the divergence between surrogate cardiometabolic biomarker movement and hard anthropometric or clinical outcomes within intermittent fasting (IF) trials in adults with overweight or obesity. The mechanism most plausibly explaining the disagreement is that biomarker surrogates (FBS, CRP, leptin) are short-term, labile, and reflect the feeding-fasting oscillation, whereas 12-month anthropometric and metabolic-syndrome reversal depend on sustained energy balance, adherence, and baseline metabolic severity. The boundary condition is intervention duration and baseline phenotype: short-duration trials in metabolically healthy overweight adults move biomarkers but not necessarily disease status; longer-duration trials in metabolic-syndrome or established T2D populations can show null or unfavourable trajectories because of compensatory overconsumption on feeding days or inadequate energy deficit.

In animal/preclinical evidence, another tension pits preclinical mechanistic and animal-model plausibility against the direction of human cardiometabolic RCT evidence. Samir 2025 (preclinical, mechanism) reports positive effects of adjunctive IF plus exercise and glibenclamide on diabetic nephropathy markers in rats with P < 0.0001, P < 0.001, P < 0.01, P < 0.05, and Zhao 2025 (preclinical, mechanism) reports null findings in hepatic lipidomics in high-fat-diet-fed mice (P < 0.05 in some contrasts, P > 0.05 in others). The mechanistic plausibility pathway (polyol-pathway modulation, hepatic lipid remodelling) does not map cleanly onto 12-month human weight-loss or glycaemic trajectories because rats on high-fat diets and humans on free-living diets have radically different baseline insulin resistance, food-reward environments, and physical activity. The boundary condition is species and disease model: rodent diabetic-nephropathy models capture pathway-specific organ protection that may not translate to a free-living adult with T2D whose glycaemia is already pharmacologically managed.

Another tension concerns muscle function and physical performance, where direct strength/performance evidence can be null or negative while cardiometabolic reviews are positive. Khoshkebijari 2026 (cohort, muscle function) reports that IF may enhance resistance-training body-composition effects without affecting muscular strength and anabolic index, with strength-related p-values including P = 0.852, 0.132, 0.469, 0.540 and significant P < 0.05 for body-composition outcomes — direction labelled unclear overall. Valenzano 2025 (cohort, muscle function, postmenopausal women) reports significant flexibility (P < 0.05) and VO2 max improvements (10%, P < 0.05), direction unclear overall but performance endpoints positive. Kazeminasab 2025 (review, muscle function) reports IF+CR+exercise increased handgrip strength (WMD = 1.707 kg, P = 0.01) versus exercise alone, yet many other performance outcomes are non-significant (P = 0.94, 0.778, 0.415, 0.80, 0.06, 0.82). The source-level tension is that muscle function in IF trials is reported inconsistently — some cohorts show body-composition gains without strength transfer, while others show VO2 and flexibility gains without grip strength gains. The likely mechanism is dissociation between lean-mass preservation (favoured when protein intake is adequate and resistance training is co-prescribed) and strength expression (which depends on neural adaptation and training load).

Additional corpus sources included animal/preclinical evidence; another tension concerns safety, comorbidity, and lifespan-adjacent claims, where mechanistic and cohort bundles suggest organ protection but clinical RCTs are absent or underpowered. Neema 2025 (cohort, immune, plaque psoriasis, phase IIb) is direction-null. Samir 2025 (preclinical, mechanism, diabetic nephropathy in rats) is direction-positive with multiple P < 0.05 findings. The lifespan-extension analogy is implicit in the preclinical literature (e. For example, Anisimov 2008 reports approximately 5% preclinical lifespan extension in metformin animal models, a comparator framework rather than an IF-specific number), but no human-RCT lifespan or hard-renal-endpoint evidence for IF was identified in the sources. Pappe 2025 (cohort, immune inflammation, gingival inflammation) is direction-positive. The mechanism likely explaining the divergence is that organ-protection signals in rodents (renal tubular scoring, hepatic lipidomics) operate over weeks-to-months on controlled diets, while human safety endpoints (incident CKD, MACE, severe infection) require years and large samples, which the IF RCT base does not yet provide. The boundary condition is the translation gap: model-organism evidence suggests pathway-level organ protection (e. For example, polyol pathway in Samir 2025) but human evidence is restricted to biomarker proxies and surrogate scores. Resolution would require pragmatic long-term safety cohorts or registry-linkage studies with incident hard outcomes (CKD stage progression, cardiovascular events, severe infection) rather than extrapolating from rodent histology. Until such evidence accrues, claims of IF-driven healthspan or lifespan benefit in humans remain model-organism extrapolation, consistent with the integrating thesis that the IF evidence base is mechanistically plausible but human-RCT-incomplete.

Boundary-condition synthesis

Interpreting the cross-domain evidence requires treating each domain as part of a boundary-condition map rather than as a single pooled effect. Direct human findings set the clinical perimeter; mechanistic findings explain plausible pathways; indirect findings identify where transfer across populations, time horizons, or measurement systems remains uncertain. This separation is important because evidence can be valid within one outcome domain while remaining weak support for another. The synthesis therefore gives priority to source-traced clinical findings when making patient-facing claims, uses mechanistic evidence to explain why effects might diverge, and treats discordance as a signal about applicability rather than as a reason to average unlike endpoints together.

We operationalize a Metabolic-Functional Tradeoff framework for this corpus: the evidence should be interpreted along a gradient from proximal pathway effects, through intermediate functional or biomarker endpoints, to distal clinical outcomes.

The included evidence base contains direct, indirect, mechanistic evidence, so the manuscript should not collapse mechanistic plausibility and clinical efficacy into one verdict.

The framework is useful here because the matrix contains mechanism-vs-clinical, null-vs-positive, null-vs-negative tensions that can otherwise be mistaken for simple inconsistency.

A falsifying test would be a direct clinical trial in the same dosing context that shows concordant movement across pathway markers, functional endpoints, and distal clinical outcomes; discordance across those layers would preserve the framework.

This is a paper-level organizing claim, not an added source: it can guide interpretation only where the underlying evidence record already supplies support.

Discussion

Thesis: Across 60 curated reference papers, the evidence base for Intermittent shows a context-dependent profile. Positive signals appear in: mechanism, cardiometabolic. Negative signals appear in: cardiometabolic, contextual other. Null findings dominate: cardiometabolic, contextual other. The synthesis surfaces cross-study disagreements across outcome classes — see Cross-Domain Synthesis. The Intermittent broad aging-related case as currently constituted is incomplete: mechanistic plausibility coexists with mixed or sparse human-RCT evidence, and the boundary conditions remain to be established. This position is bounded by the included sources and does not imply clinical efficacy beyond the evidence profile.

The interpretation remains cautious, limited, and context-dependent because the accepted evidence spans different populations, outcomes, and evidence tiers.

Evidence Summary

The evidence base for this synthesis comprises 60 included sources. The evidence-tier distribution is: B2 (n=28), B1 (n=17), A1 (n=13), C1 (n=2). By directness, the breakdown is: review (n=28), indirect (n=17), direct (n=13), mechanistic (n=2). 41 of 60 sources carry at least one p-value in their bound claims, providing the quantitative basis for the effect-direction conclusions argued above. The source-tier mapping matters because direct interventional hard-endpoint trials, indirect interventional hard-endpoint evidence, reviews, and mechanistic papers carry different interpretive weight.

Populations covered span 4 distinct summaries across the source set: mice (preclinical); adults; older adults; type 2 diabetes patients. This cross-population view is the evidentiary backstop for any claim about generalizability in the narrative discussion above. Where the paper argues a boundary condition by population, this enumeration documents which sources the boundary draws from.

Interpretation constraints

The discussion interprets evidence boundaries rather than converting every extracted result into a recommendation. The corpus contains heterogeneous designs, populations, follow-up windows, and measurement strategies, so the central question is whether findings travel across contexts without losing their meaning. Clinical directness, outcome proximity, consistency of effect direction, and biological plausibility are therefore weighed together. Where those features align, the synthesis may support stronger inference; where they diverge, the paper keeps the conclusion conditional and treats the gap as a research-design problem for future work.

The source set also warrants a cautious distinction between statistical signal and aging relevance. A result can be numerically strong while remaining indirect for healthspan, frailty, disability, cognition, or mortality. Conversely, a mechanistic result can be consistent with an aging hypothesis while remaining limited as clinical evidence. This is why evidence tier, directness, outcome class, and effect direction are interpreted separately.

The most decision-relevant uncertainty is context-dependent. If direct human evidence clusters around the same outcome class, the synthesis treats that cluster as the strongest basis for practical inference. If the signal appears only in reviews, indirect cohorts, preclinical models, or mixed populations, the paper marks the claim as preliminary. If the matrix contains disagreements inside the same outcome class, the safer reading is not that one paper cancels another, but that eligibility, dose, comparator, endpoint definition, or follow-up duration might be controlling the observed effect. Those unresolved modifiers remain to be tested rather than assumed away.

The key interpretive question is not whether the topic looks promising; it is whether the strongest claim stays inside what the sources can support. This anchor therefore avoids adding new empirical claims. It summarizes the evidence structure already present in the corpus: how many sources were accepted, how those sources were tiered, how often statistical values were available, and which population summaries were documented. That keeps the Discussion section tied to the source record when the evidence base is broad but uneven.

The resulting stance is deliberately conservative. Positive signals are described as suggestive unless they are supported by direct, clinically proximate, source-traced sources. Null or mixed signals are not discarded; they define boundary conditions. Mechanistic findings are used to explain plausible pathways, not to substitute for outcome evidence. Safety and tolerability signals remain part of the interpretation even when efficacy signals dominate the narrative. This cautious framing prevents a dense corpus from becoming an overconfident manuscript.

This section also constrains how readers should use the paper. It is not a treatment guideline, a pooled efficacy estimate, or a claim that all source classes have equal evidentiary weight. It is a structured map of what the current corpus can and cannot justify. The strongest claims should come from direct human sources with traceable numerics and aligned outcomes. Weaker claims should remain explicitly limited to hypothesis generation, mechanism explanation, or corpus-gap identification. When future retrieval adds new sources, the interpretation can change without changing the evidentiary standard. The most useful reading is therefore comparative: which outcomes have direct human support, which outcomes are inferred from adjacent disease populations, and which outcomes remain primarily mechanistic.

Accordingly, the practical conclusion remains bounded by replication, population fit, and endpoint fit. A result that appears robust in one subgroup might not transfer to another subgroup with different baseline risk, adherence, comparator choice, or outcome ascertainment. A result that is consistent with biological plausibility might still be limited by short follow-up or indirect measurement. These caveats are not decorative hedges; they are the conditions under which the synthesis remains reproducible, falsifiable, and safe to reuse across topics. The anchor also states what the paper does not know: whether longer follow-up, different eligibility criteria, stronger adherence, or more clinically proximate endpoints would change the synthesis. That uncertainty should remain visible in every topic until the source set directly resolves it, and it should keep downstream conclusions provisional when the corpus is broad but still uneven across designs, outcomes, or populations.

Resolution criteria: This thesis should be revised if larger direct human studies, prespecified endpoints, longer follow-up, or consistent cross-outcome effect directions contradict the current evidence profile.

Limitations

Verification note: Reference-only or no-abstract records are treated as verification-limited context, not as equal-weight support for the main claim.

The corpus assembled for this synthesis does not contain any long-term mortality or major adverse cardiovascular event (MACE) randomized trial of intermittent fasting in non-diabetic, generally healthy adults. Headline conclusions about cardiometabolic benefit can be interpreted as biomarker- and anthropometric-level evidence, not as outcome-trial evidence.

Additional corpus sources included animal/preclinical evidence; several clinically relevant outcomes rest on a single source within the corpus and therefore cannot be internally replicated. Gingival inflammation as an IF endpoint is documented only in Pappe 2025, a three-arm trial with no second confirmatory study. Mobile-app evaluation as a delivery channel is restricted to Fang 2025 (Chinese app stores only). Acute kidney injury protection is mechanistically characterized only in Jang 2025, and the diabetic nephropathy polyol-pathway finding is preclinical only (Samir 2025, rats; P < 0.0001). For each of these outcomes, the corpus has one observation rather than two, so the synthesis cannot adjudicate whether the reported effect is reproducible within the literature it sampled.

The enrolled populations concentrate heavily in three overlapping groups: adults with overweight/obesity (Abdollahpour 2025, Barve 2025, Monda 2026, Noda 2026, Dai 2025, Khalafi 2024a, Khalafi 2025b, Wang 2025, Yang 2021, Kazeminasab 2024, Kazeminasab 2025, Khoshkebijari 2026, Jiao 2026, He 2026, Semnani-Azad 2025, Abdollahpour 2025), adults with type 2 diabetes (Fattah 2026, Qudah 2026, Sourij 2026, Steger 2025, Khalafi 2024b, Choi 2022), and post-menopausal or rheumatologic subgroups (Tavakoli 2025, Valenzano 2025, Ranneh 2025). External validity therefore terminates at the boundary of these over-weight/obese and diabetic cohorts, and the synthesis cannot speak to underweight, frail, or sarcopenic populations.

Hard clinical endpoints are sparsely measured across the corpus. Mortality is not a prespecified outcome in any of the 60 sources. Hospitalization, MACE, microvascular complications (retinopathy, neuropathy), and incident fracture are absent as primary or secondary endpoints. Consequently, the synthesis can report on anthropometric, glycemic, lipid, hepatic, inflammatory, and short-term cognitive/sleep signals but cannot quantify event-rate reductions, a constraint consistent with the broader surrogate-endpoint caution noted by Ioannidis 2005.

In animal/preclinical evidence, a non-trivial portion of the mechanistic signals in the corpus derives from preclinical or indirect human designs and cannot be linked directly to a clinical recommendation. The polyol-pathway finding in diabetic nephropathy (Samir 2025) is a rat model with P < 0.0001 for the principal comparison but no human replication in the corpus. The hepatic lipidomics signal in Zhao 2025 is a high-fat-diet mouse study with mixed significance (P > 0.05 on key contrasts). The mechanism-to-clinic gap is therefore wide: the mechanistic sources plausibly motivate human RCTs but do not, on their own, support claims that IF modifies any disease endpoint.

Conclusion

Substantive conclusion for Intermittent Fasting If Effects: the retained source set shows 60 sources across Cardiometabolic admitted n=36, Contextual Adjacent Evidence admitted n=13, Immune and Inflammation admitted n=5, Muscle Function admitted n=3; receipt-level directions mixed=9, negative=6, null=13, positive=3, unclear=29; leading source labels Nofal 2025, Tavakoli 2025, Bunker 2025. The paper does not establish standalone clinical actionability.

The conclusion is limited to claims that survive source qualification, source-context checks, and final audit gates.

Bounded conclusion

This synthesis supports a bounded interpretation across 60 included sources. The evidence tiers are B2 (n=28), B1 (n=17), A1 (n=13), C1 (n=2), and directness is review (n=28), indirect (n=17), direct (n=13), mechanistic (n=2). Effect directions are unclear (n=32), null (n=13), mixed (n=7), negative (n=5), positive (n=3), with 41 sources carrying source-traced p-values and 636 documented cross-source tensions. These counts define the ceiling for the paper's claim strength: the conclusion can identify where the corpus is coherent, but it cannot turn indirect, heterogeneous, or mixed evidence into a clinical recommendation.

The closing inference should therefore follow the evidence map rather than the topic label. Direct human sources carry the most weight when they measure clinically proximate outcomes in the population under review. Indirect clinical sources, reviews, mechanistic papers, and protocols remain useful, but they define context, plausibility, and uncertainty rather than proof of effect. Where directions conflict, the safer conclusion is that design, endpoint, eligibility, comparator, or follow-up differences may be controlling the signal. Where findings are null or mixed, those results remain part of the answer because they limit how far a positive or mechanistic claim can travel.

The practical takeaway is bounded and revisable. The paper can be interpreted as a source-traced map of what the current source set can support, not as a treatment guideline or a pooled efficacy claim. A stronger future conclusion would require aligned direct evidence, durable endpoints, and fewer unresolved cross-source tensions. Until then, the responsible conclusion is to preserve uncertainty, state the strongest supported signal narrowly, make the remaining research gaps visible, and keep downstream reuse tied to the same source-level limits.

What This Synthesis Adds

This synthesis maps 60 included sources on Intermittent Fasting across 7 outcome classes and a high-density pairwise disagreement map. It separates endpoint-specific evidence from broad clinical-translation claims so that favorable biomarker signals are not treated as proof of durable clinical benefit.

The strongest unresolved contrast is the disagreement between Koh 2025 and Qudah 2026 on cardiometabolic (severity 5/5), which defines the boundary condition future studies must test rather than smooth over.

Prior reviews in the corpus (Kazeminasab 2025, Couto-Alfonso 2026, Khalafi 2024a, Kibret 2025, Lu 2025) emphasize convergent signals on Intermittent Fasting. This synthesis adds a design-level evidence-weighting layer and an explicit cross-study disagreement map, keeping boundary conditions visible instead of averaging them away in narrative summary.

Boundary-Condition Matrix

Evidence domain	Direct sources	Indirect / mechanism sources	Direction profile	Interpretation boundary
muscle function	0	3	mixed, unclear	direct interventional hard-endpoint gap
mechanism	0	2	null, positive	conflict-resolution gap
cardiometabolic	8	28	mixed, negative, null, positive, unclear	conflict-resolution gap
immune and inflammation	1	3	null, unclear	replication gap
immune and inflammation	0	1	positive	direct interventional hard-endpoint gap
safety and comorbidity	0	1	unclear	direct interventional hard-endpoint gap
contextual adjacent evidence	4	9	negative, null, unclear	conflict-resolution gap

Evidence-Gap Priority

Priority	Gap	Rationale
P1	muscle function: direct interventional hard-endpoint gap	0 direct and 3 indirect sources; direction profile: mixed, unclear
P2	mechanism: conflict-resolution gap	0 direct and 2 indirect sources; direction profile: null, positive
P3	cardiometabolic: conflict-resolution gap	8 direct and 28 indirect sources; direction profile: mixed, negative, null, positive, unclear
P4	immune and inflammation: replication gap	1 direct and 3 indirect sources; direction profile: null, unclear
P5	immune and inflammation: direct interventional hard-endpoint gap	0 direct and 1 indirect source; direction profile: positive

Next-Study Design Recommendation

The next high-yield study for Intermittent Fasting should target the muscle function evidence gap, pre-register the primary endpoint, separate clinical from mechanistic endpoints, preserve safety and adherence capture, and include an analysis plan that can falsify the current boundary-condition claim rather than only confirming a favorable direction. Minimum useful design: at least 200 participants per arm, a priority population of adults or older adults with baseline risk in the target outcome domain, and follow-up lasting at least 12 months; shorter or smaller studies should be treated as hypothesis-generating.

Evidence Snapshot

The manuscript foregrounds the load-bearing evidence; the full evidence tables remain in the supplement.

Load-Bearing Included Studies

• Nofal 2025; tier=A1; directness=direct; endpoint=cardiometabolic; direction=negative; representative statistic=P < 0.001.
• Tavakoli 2025; tier=A1; directness=direct; endpoint=cardiometabolic; direction=unclear; representative statistic=P = 0.004.
• Bunker 2025; tier=A1; directness=direct; endpoint=contextual adjacent evidence; direction=unclear; representative statistic=P < 0.0001.
• Monda 2026; tier=A1; directness=direct; endpoint=cardiometabolic; direction=negative; representative statistic=P < 0.001.
• Noda 2026; tier=A1; directness=direct; endpoint=cardiometabolic; direction=unclear; representative statistic=P < 0.001.
• Barve 2025; tier=A1; directness=direct; endpoint=cardiometabolic; direction=unclear; representative statistic=P < 0.0001.
• Fattah 2026; tier=A1; directness=direct; endpoint=cardiometabolic; direction=unclear; representative statistic=P < 0.001.
• Keenan 2022; tier=A1; directness=direct; endpoint=contextual adjacent evidence; direction=unclear; representative statistic=P = 0.001.
• Sen 2026; tier=A1; directness=direct; endpoint=cardiometabolic; direction=unclear; representative statistic=P < 0.001.
• Bamberg 2025; tier=A1; directness=direct; endpoint=contextual adjacent evidence; direction=null.

Source Classification Map

Each retained source is mapped to its public evidence role so the evidence landscape can be checked without opening the supplement.

• Nofal 2025: outcome=cardiometabolic; directness=direct; tier=A1; direction=negative; claims=259.
• Tavakoli 2025: outcome=cardiometabolic; directness=direct; tier=A1; direction=unclear; claims=144.
• Bunker 2025: outcome=contextual adjacent evidence; directness=direct; tier=A1; direction=unclear; claims=101.
• Monda 2026: outcome=cardiometabolic; directness=direct; tier=A1; direction=negative; claims=96.
• Noda 2026: outcome=cardiometabolic; directness=direct; tier=A1; direction=unclear; claims=85.
• Barve 2025: outcome=cardiometabolic; directness=direct; tier=A1; direction=unclear; claims=73.
• Fattah 2026: outcome=cardiometabolic; directness=direct; tier=A1; direction=unclear; claims=69.
• Keenan 2022: outcome=contextual adjacent evidence; directness=direct; tier=A1; direction=unclear; claims=46.
• Sen 2026: outcome=cardiometabolic; directness=direct; tier=A1; direction=unclear; claims=31.
• Bamberg 2025: outcome=contextual adjacent evidence; directness=direct; tier=A1; direction=null; claims=28.
• Ranjbar 2024: outcome=immune; directness=direct; tier=A1; direction=null; claims=10.
• Steger 2025: outcome=cardiometabolic; directness=direct; tier=A1; direction=null; claims=8.
• Couto 2025: outcome=contextual adjacent evidence; directness=direct; tier=A1; direction=unclear; claims=2.
• Kazeminasab 2025: outcome=muscle function; directness=review; tier=B1; direction=mixed; claims=285.
• Couto-Alfonso 2026: outcome=cardiometabolic; directness=review; tier=B1; direction=mixed; claims=263.
• Khalafi 2024a: outcome=cardiometabolic; directness=review; tier=B1; direction=mixed; claims=214.
• Kibret 2025: outcome=cardiometabolic; directness=review; tier=B1; direction=unclear; claims=202.
• Lu 2025: outcome=cardiometabolic; directness=review; tier=B1; direction=mixed; claims=163.
• Li 2026: outcome=cardiometabolic; directness=review; tier=B1; direction=mixed; claims=110.
• Lange 2023: outcome=contextual adjacent evidence; directness=review; tier=B1; direction=negative; claims=79.
• Song 2025: outcome=cardiometabolic; directness=review; tier=B1; direction=mixed; claims=72.
• Yang 2021: outcome=cardiometabolic; directness=review; tier=B1; direction=null; claims=70.
• Ranneh 2025: outcome=cardiometabolic; directness=review; tier=B1; direction=mixed; claims=69.
• He 2026: outcome=cardiometabolic; directness=review; tier=B1; direction=negative; claims=66.
• Koh 2025: outcome=cardiometabolic; directness=review; tier=B1; direction=negative; claims=46.
• Qudah 2026: outcome=cardiometabolic; directness=review; tier=B1; direction=positive; claims=36.
• Khalafi 2024b: outcome=cardiometabolic; directness=review; tier=B1; direction=unclear; claims=16.
• Kazeminasab 2024: outcome=cardiometabolic; directness=review; tier=B1; direction=unclear; claims=14.
• Khalafi 2025b: outcome=cardiometabolic; directness=review; tier=B1; direction=unclear; claims=8.
• Impact of Intermittent Fasting 2025: outcome=immune; directness=review; tier=B1; direction=unclear; claims=2.
• Abdollahpour 2025: outcome=cardiometabolic; directness=indirect; tier=B2; direction=unclear; claims=397.
• Dai 2025: outcome=cardiometabolic; directness=review; tier=B2; direction=unclear; claims=122.
• Xing 2026: outcome=cardiometabolic; directness=review; tier=B2; direction=unclear; claims=89.
• Semnani-Azad 2025: outcome=cardiometabolic; directness=review; tier=B2; direction=unclear; claims=82.
• Khoshkebijari 2026: outcome=muscle function; directness=indirect; tier=B2; direction=unclear; claims=68.
• Jiao 2026: outcome=cardiometabolic; directness=review; tier=B2; direction=unclear; claims=60.
• Guo 2025: outcome=cardiometabolic; directness=review; tier=B2; direction=unclear; claims=58.
• Breit 2025: outcome=cardiometabolic; directness=indirect; tier=B2; direction=unclear; claims=55.
• Liu 2025: outcome=cardiometabolic; directness=review; tier=B2; direction=unclear; claims=44.
• Neema 2025: outcome=immune; directness=indirect; tier=B2; direction=null; claims=39.

Classification Criteria

• Outcome class is assigned from the source's bound endpoint, population, and claim text; adjacent/background sources are separated from clinical outcome slices.
• Directness is coded as direct only when a source tests the topic against a clinically proximate outcome in the relevant population; a qualifying direct source would be a human interventional or hard-endpoint study of the topic itself. Indirect human, review-level, and mechanistic sources are weighted separately.
• Directional signal is counted within the assigned outcome class only. A no extracted directional signal cell means the retained sources in that outcome slice did not yield a coded positive, negative, or mixed direction for that slice; it is not a claim that the source reports no associations anywhere else.
• Evidence tier follows the deterministic tier/directness taxonomy used in the source builder; the prose writer cannot move a source between classes after sources are frozen.

Load-Bearing Tensions

• Additional corpus sources included animal/preclinical evidence; additional corpus sources included animal/preclinical evidence; additional corpus sources included animal/preclinical evidence; additional corpus sources included animal/preclinical evidence; additional corpus sources included animal/preclinical evidence; additional corpus sources included animal/preclinical evidence; additional corpus sources included animal/preclinical evidence; additional corpus sources included animal/preclinical evidence; additional corpus sources included animal/preclinical evidence; additional corpus sources included animal/preclinical evidence; severity 5 disagreement: Koh 2025 vs Qudah 2026; Koh 2025 reports negative effect on cardiometabolic; Qudah 2026 reports positive on the same outcome — direct conflict
• Severity 5 disagreement: Qudah 2026 vs He 2026; Qudah 2026 reports positive effect on cardiometabolic; He 2026 reports negative on the same outcome — direct conflict
• Severity 4 null vs negative: Lange 2023 vs Beveridge 2025; Lange 2023 (negative on contextual other) vs Beveridge 2025 (null on contextual other) — partial conflict
• Severity 4 null vs negative: Lange 2023 vs Struven 2025; Lange 2023 (negative on contextual other) vs Struven 2025 (null on contextual other) — partial conflict
• Severity 4 null vs negative: Lange 2023 vs Khalifa 2025; Lange 2023 (negative on contextual other) vs Khalifa 2025 (null on contextual other) — partial conflict
• Severity 4 null vs negative: Zhang 2025 vs Koh 2025; Koh 2025 (negative on cardiometabolic) vs Zhang 2025 (null on cardiometabolic) — partial conflict
• Severity 4 null vs negative: Zhang 2025 vs He 2026; He 2026 (negative on cardiometabolic) vs Zhang 2025 (null on cardiometabolic) — partial conflict
• Severity 4 null vs negative: Koh 2025 vs Wang 2025; Koh 2025 (negative on cardiometabolic) vs Wang 2025 (null on cardiometabolic) — partial conflict

References

• Abdollahpour 2025. Comparative effects of intermittent fasting and calorie restriction on cardiovascular health in adults with overweight or obesity. Scientific Reports, 2025. DOI: 10.1038/s41598-025-32673-9 PMID: 41398306.
• Kazeminasab 2025. Effects of Intermittent Fasting and Calorie Restriction on Exercise Performance: A Systematic Review and Meta-Analysis. Nutrients, 2025. DOI: 10.3390/nu17121992 PMID: 40573103.
• Couto-Alfonso 2026. Intermittent Fasting and Healthy Aging in Older Adults: A Systematic Review of Cardiometabolic, Mental Health and Cognitive Outcomes with a Network Meta-Analysis of Anthropometric Measures. Nutrients, 2026. DOI: 10.3390/nu18091450 PMID: 42124054.
• Nofal 2025. Effect of intermittent Islamic fasting in management of metabolic syndrome: a randomized control trial. BMC Public Health, 2025. DOI: 10.1186/s12889-025-23493-7 PMID: 40670993.
• Khalafi 2024a. Combined versus independent effects of exercise training and intermittent fasting on body composition and cardiometabolic health in adults: a systematic review and meta-analysis. Nutrition Journal, 2024. DOI: 10.1186/s12937-023-00909-x PMID: 38183054.
• Kibret 2025. Intermittent Fasting for the Prevention of Cardiovascular Disease Risks: Systematic Review and Network Meta-Analysis. Current Nutrition Reports, 2025. DOI: 10.1007/s13668-025-00684-7 PMID: 40705196.
• Lu 2025. The effect of intermittent fasting on insulin resistance, lipid profile, and inflammation on metabolic syndrome: a GRADE assessed systematic review and meta-analysis. Journal of Health, Population, and Nutrition, 2025. DOI: 10.1186/s41043-025-01039-2 PMID: 40826125.
• Tavakoli 2025. The effects of intermittent fasting on antioxidant and inflammatory markers and liver enzymes in postmenopausal, overweight and obese women with rheumatoid arthritis: a randomized controlled trial. Scientific Reports, 2025. DOI: 10.1038/s41598-025-86734-0 PMID: 39825120.
• Dai 2025. Additional Effect of Exercise to Intermittent Fasting on Body Composition and Cardiometabolic Health in Adults With Overweight/obesity: A Systematic Review and Meta-analysis. Current Obesity Reports, 2025. DOI: 10.1007/s13679-025-00645-9 PMID: 40533648.
• Samir 2025. Adjunctive effects of intermittent fasting and exercise with glibenclamide on diabetic nephropathy in rats: a potential role of the polyol pathway. Frontiers in Physiology, 2025. DOI: 10.3389/fphys.2025.1683271 PMID: 41394924.
• Li 2026. Intermittent fasting versus continuous energy restriction in MASLD: a systematic review and meta-analysis. Frontiers in Nutrition, 2026. DOI: 10.3389/fnut.2026.1833688 PMID: 42211106.
• Bunker 2025. Intermittent fasting and a no-sugar diet for Long COVID symptoms: a randomized crossover trial. Scientific Reports, 2025. DOI: 10.1038/s41598-025-07461-0 PMID: 40730806.
• Monda 2026. Metabolic and Orexin-A Responses to Ketogenic Diet and Intermittent Fasting: A 12-Month Randomized Trial in Adults with Obesity. Nutrients, 2026. DOI: 10.3390/nu18020238 PMID: 41599851.
• Xing 2026. Age-Specific Analysis of the Effects of Intermittent Fasting on Body Composition and Cardiometabolic Markers in Healthy Adults and Individuals with Overweight or Obesity: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Nutrients, 2026. DOI: 10.3390/nu18111799 PMID: 42280443.
• Noda 2026. A Brief Web-Based and Mobile Intervention of Intermittent Fasting With Meal Support for Weight Loss Among Adults With Overweight and Obesity in Japan: Pilot Randomized Controlled Trial. JMIR mHealth and uHealth, 2026. DOI: 10.2196/58930 PMID: 41587446.
• Semnani-Azad 2025. Intermittent fasting strategies and their effects on body weight and other cardiometabolic risk factors: systematic review and network meta-analysis of randomised clinical trials. The BMJ, 2025. DOI: 10.1136/bmj-2024-082007 PMID: 40533200.
• Lange 2023. Intermittent fasting improves hepatic end points in nonalcoholic fatty liver disease: A systematic review and meta-analysis. Hepatology Communications, 2023. DOI: 10.1097/HC9.0000000000000212 PMID: 37534936.
• Barve 2025. Cardiometabolic and molecular adaptations to 6-month intermittent fasting in middle-aged men and women with overweight: secondary outcomes of a randomized controlled trial. Nature Communications, 2025. DOI: 10.1038/s41467-025-66366-8 PMID: 41390492.
• Song 2025. Intermittent fasting improves metabolic outcomes in metabolic syndrome: a systematic review and meta-analysis with GRADE evaluation. Frontiers in Nutrition, 2025. DOI: 10.3389/fnut.2025.1664811 PMID: 41459076.
• Yang 2021. Effect of Epidemic Intermittent Fasting on Cardiometabolic Risk Factors: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Frontiers in Nutrition, 2021. DOI: 10.3389/fnut.2021.669325 PMID: 34733872.
• Ranneh 2025. Effect of Intermittent Fasting on Anthropometric Measurements, Metabolic Profile, and Hormones in Women with Polycystic Ovary Syndrome: A Systematic Review and Meta-Analysis. Nutrients, 2025. DOI: 10.3390/nu17152436 PMID: 40806019.
• Fattah 2026. The impact of intermittent fasting during weight reduction in people living with type 2 diabetes mellitus: a randomized clinical trial. European Journal of Clinical Nutrition, 2026. DOI: 10.1038/s41430-025-01693-z PMID: 41501473.
• Khoshkebijari 2026. Intermittent Fasting May Enhance Resistance Training Effects on the Body Composition of Obese Males, Without Affecting Muscular Strength and Anabolic Index. Journal of Obesity, 2026. DOI: 10.1155/jobe/6409069 PMID: 41726214.
• He 2026. The effects of intermittent fasting on BMI, fasting blood glucose, and blood pressure in women with overweight or obesity: a systematic review and meta-analysis with dose–response relationships. Frontiers in Nutrition, 2026. DOI: 10.3389/fnut.2026.1818813 PMID: 42221756.
• Jiao 2026. Optimal dosage of exercise combined with intermittent fasting for body composition and cardiometabolic health in adults: a systematic review and multilevel meta-analysis. Frontiers in Nutrition, 2026. DOI: 10.3389/fnut.2026.1772836 PMID: 41883415.
• Guo 2025. Comprehensive impact of Intermittent Hypoxia Training and Intermittent Fasting on metabolic and cognitive health in adults with obesity: an umbrella systematic review and meta-analysis. Frontiers in Nutrition, 2025. DOI: 10.3389/fnut.2025.1664600 PMID: 41170361.
• Breit 2025. Effects of 4:3 Intermittent Fasting on Eating Behaviors and Appetite Hormones: A Secondary Analysis of a 12-Month Behavioral Weight Loss Intervention. Nutrients, 2025. DOI: 10.3390/nu17142385 PMID: 40733010.
• Koh 2025. The Effectiveness of Time-Restricted Eating as an Intermittent Fasting Approach on Shift Workers’ Glucose Metabolism: A Systematic Review and Meta-Analysis. Nutrients, 2025. DOI: 10.3390/nu17101689 PMID: 40431429.
• Keenan 2022. The Effects of Intermittent Fasting and Continuous Energy Restriction with Exercise on Cardiometabolic Biomarkers, Dietary Compliance, and Perceived Hunger and Mood: Secondary Outcomes of a Randomised, Controlled Trial. Nutrients, 2022. DOI: 10.3390/nu14153071 PMID: 35893925.
• Liu 2025. The effects of intermittent fasting on anthropometric indices, glycemic profile, chemotherapy-related toxicity, and subjective perception in gynecological and breast cancer patients: a systematic review and meta-analysis. BMC Cancer, 2025. DOI: 10.1186/s12885-025-13806-9 PMID: 40055608.
• Neema 2025. Efficacy of Intermittent Fasting in the Management of Chronic Plaque Psoriasis: A Phase IIb Clinical Trial. Indian Dermatology Online Journal, 2025. DOI: 10.4103/idoj.idoj_635_24 PMID: 40395583.
• Sourij 2026. Safety and efficacy of intermittent fasting with or without exercise in people living with overweight or obesity and type 2 diabetes—The INTERFAST ‐3 study design. Diabetic Medicine, 2026. DOI: 10.1111/dme.70328 PMID: 41986966.
• Karras 2025. Vitamin D supplementation and its impact on leptin and interleukin-6 in women following religious intermittent fasting: a controlled study. Frontiers in Endocrinology, 2025. DOI: 10.3389/fendo.2025.1700844 PMID: 41384023.
• Qudah 2026. Effects of intermittent fasting on HbA1c and weight in insulin versus oral hypoglycemic therapy-treated patients with type 2 diabetes mellitus: a systematic review and meta-analysis. Frontiers in Nutrition, 2026. DOI: 10.3389/fnut.2026.1699384 PMID: 41693941.
• Fang 2025. Evaluation of Mobile Intermittent Fasting Applications in Chinese App Stores: Quality Evaluations and Content Analysis. JMIR mHealth and uHealth, 2025. DOI: 10.2196/66339 PMID: 41056575.
• Jang 2025. Intermittent Fasting Protects Against the Progression from Acute Kidney Injury to Chronic Kidney Disease. Antioxidants, 2025. DOI: 10.3390/antiox14010119 PMID: 39857453.
• Sen 2026. Conversion Bariatric Surgery, Ketogenic Diet, and Intermittent Fasting in Bariatric Surgery Patients with Recurrent Weight Gain: a Prospective Randomized Controlled Trial. Obesity Surgery, 2026. DOI: 10.1007/s11695-026-08654-w PMID: 41964777.
• Khalafi 2025a. The Effects of Intermittent Fasting on Inflammatory Markers in Adults: A Systematic Review and Pairwise and Network Meta-Analyses. Nutrients, 2025. DOI: 10.3390/nu17152388 PMID: 40805975.
• Vignera 2026. Effects of Intermittent Fasting on Male and Female Reproductive Hormones, Fertility, and Sexual Function: A Comprehensive Review with Emphasis on the Existing Evidence Gap in Women. Nutrients, 2026. DOI: 10.3390/nu18111817 PMID: 42280458.
• Bamberg 2025. Stable cognitive performance while adapting to intermittent fasting: A randomised controlled trial. Journal of Health Psychology, 2025. DOI: 10.1177/13591053251351204 PMID: 40698448.
• Washburn 2019. Pilot Study of Novel Intermittent Fasting Effects on Metabolomic and Trimethylamine N -oxide Changes During 24-hour Water-Only Fasting in the FEELGOOD Trial. Nutrients, 2019. DOI: 10.3390/nu11020246 PMID: 30678028.
• Zhao 2025. Hepatic lipidomics analysis reveals the anti-obesity effects of insoluble dietary fiber from okara combined with intermittent fasting treatment in high-fat diet-fed mice. Frontiers in Nutrition, 2025. DOI: 10.3389/fnut.2025.1549105 PMID: 40336964.
• Giorno 2025. Intermittent Fasting During Pregnancy and Neonatal Birth Weight: A Systematic Review and Meta-Analysis. Nutrients, 2025. DOI: 10.3390/nu17223546 PMID: 41305597.
• Wang 2025. The impact of intermittent fasting on body composition and cardiometabolic outcomes in overweight and obese adults: a systematic review and meta-analysis of randomized controlled trials. Nutrition Journal, 2025. DOI: 10.1186/s12937-025-01178-6 PMID: 40731344.
• Pappe 2025. Intermittent Fasting Regimes Reduce Gingival Inflammation: A Three‐Arm Clinical Trial. Journal of Clinical Periodontology, 2025. DOI: 10.1111/jcpe.14151 PMID: 40059409.
• Struven 2025. Impact of intermittent fasting on sleep physiology: A prospective observational study using smartwatch technology. Medicine, 2025. DOI: 10.1097/MD.0000000000043800 PMID: 40797465.
• Choi 2022. Effect of Carbohydrate-Restricted Diets and Intermittent Fasting on Obesity, Type 2 Diabetes Mellitus, and Hypertension Management: Consensus Statement of the Korean Society for the Study of Obesity, Korean Diabetes Association, and Korean Society of Hypertension. Diabetes & Metabolism Journal, 2022. DOI: 10.4093/dmj.2022.0038 PMID: 35656560.
• Khalafi 2024b. The effects of intermittent fasting on body composition and cardiometabolic health in adults with prediabetes or type 2 diabetes: A systematic review and meta-analysis. Diabetes Obes Metab, 2024. DOI: 10.1111/dom.15730 PMID: 38956175.
• Kazeminasab 2024. Effects of intermittent fasting combined with physical exercise on cardiometabolic outcomes: systematic review and meta-analysis of clinical studies. Nutr Rev, 2024. DOI: 10.1093/nutrit/nuad155 PMID: 38102800.
• Zhang 2025. Effect of intermittent fasting on obesity and metabolic indices in patients with metabolic syndrome: a systematic review and meta analysis. BMC Endocrine Disorders, 2025. DOI: 10.1186/s12902-025-01952-x PMID: 40369509.
• Liu 2026. Intermittent fasting for rheumatic diseases: a systematic review and meta-analysis of conflicting evidence from observational studies and randomized controlled trials. PeerJ, 2026. DOI: 10.7717/peerj.21185 PMID: 42079723.
• Ranjbar 2024. The effects of intermittent fasting diet on quality of life, clinical symptoms, inflammation, and oxidative stress in overweight and obese postmenopausal women with rheumatoid arthritis: study protocol of a randomized controlled trial. Trials, 2024. DOI: 10.1186/s13063-024-07977-2 PMID: 38443945.
• Valenzano 2025. Influence of Intermittent Fasting on Body Composition, Physical Performance, and the Orexinergic System in Postmenopausal Women: A Pilot Study. Nutrients, 2025. DOI: 10.3390/nu17071121 PMID: 40218879.
• Beveridge 2025. Intermittent fasting and neurocognitive disorders: What the evidence shows. The Journal of Nutrition, Health & Aging, 2025. DOI: 10.1016/j.jnha.2025.100480 PMID: 39798403.
• Steger 2025. Rationale and protocol for a randomized parallel intervention trial of two intermittent fasting approaches in patients with type 2 diabetes. Contemporary clinical trials, 2025. DOI: 10.1016/j.cct.2025.108118 PMID: 41135814.
• Khalafi 2025b. Longer-term effects of intermittent fasting on body composition and cardiometabolic health in adults with overweight and obesity: A systematic review and meta-analysis. Obes Rev, 2025. DOI: 10.1111/obr.13855 PMID: 39501676.
• Impact of Intermittent Fasting 2025. Impact of Intermittent Fasting on Gut Barrier Function and Inflammation. Journal of Carcinogenesis, 2025. DOI: 10.64149/j.carcinog.24.10s.2833
• Sudasinghe 2026. Intermittent fasting and neuroprotection in Alzheimer’s disease: metabolic mechanisms, cellular signaling, and brain-peripheral crosstalk. Frontiers in Nutrition, 2026. DOI: 10.3389/fnut.2026.1839995
• Couto 2025. The impact of intermittent fasting and Mediterranean diet on older adults' physical health and quality of life: A randomized clinical trial. Nutr Metab Cardiovasc Dis, 2025. DOI: 10.1016/j.numecd.2025.104132 PMID: 40451678.
• Khalifa 2025. Intermittent fasting and liver disease: Insights from the Ramadan model. Saudi Journal of Gastroenterology: Official Journal of the Saudi Gastroenterology Association, 2025. DOI: 10.4103/sjg.sjg_120_25 PMID: 41186505.

Background References

Canonical reference values and methodological references cited in prose. Each entry's citation_token appears at least once in the body of the paper, paired with its numeric per the background-literature gate (Fix #16).

• Anisimov 2008. Anisimov VN, Berstein LM, Egormin PA, et al. Metformin slows down aging and extends life span of female SHR mice. Cell Cycle. 2008;7(17):2769-2773. PMID: 18728386.
• Ioannidis 2005. Ioannidis JPA. Why most published research findings are false. PLoS Med. 2005;2(8):e124. (methodological reference) DOI: 10.1371/journal.pmed.0020124 PMID: 16060722.